{"id":16571,"date":"2024-02-26T14:28:18","date_gmt":"2024-02-26T05:28:18","guid":{"rendered":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/?page_id=16571"},"modified":"2026-01-08T15:14:33","modified_gmt":"2026-01-08T06:14:33","slug":"results","status":"publish","type":"page","link":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/department\/shinryoka\/konai\/results\/","title":{"rendered":"\u547c\u5438\u5668\u5185\u79d1 \u81e8\u5e8a\u7814\u7a76\u767a\u8868\u5b9f\u7e3e"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">\u5e73\u621028\u5e74\u5ea6\uff5e\u4ee4\u548c6\u5e74\u5ea6<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">\u4ee4\u548c6\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u8457\u66f8\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u6c17\u7ba1\u652f\u93e1\u306e\u6d17\u6d44\u30fb\u6d88\u6bd2\u6307\u91dd\uff0e\u7b39\u7530\u771f\u6ecb\u3001\u7c9f\u91ce\u66a2\u5eb7\u3001\u77f3\u7530\u6b63\u4e4b\u3001\u5185\u6751\u572d\u543e\u3001\u93d1\u6728\u5b5d\u4e4b\u3001\u9ce5\u7fbd\u535a\u660e\u3001\u7336\u6728\u514b\u5f66\u3001\u897f\u4e95\u6d0b\u4e00\u3001\u59eb\u8def\u5927\u8f14\uff0e\u65e5\u672c\u547c\u5438\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u5b66\u8853\u59d4\u54e1\u4f1a\u3000\u6c17\u7ba1\u652f\u93e1\u306e\u6d17\u6d44\u30fb\u6d88\u6bd2\u306b\u95a2\u3059\u308b\u30ef\u30fc\u30ad\u30f3\u30b0\u30b0\u30eb\u30fc\u30d7\uff0e\u6c17\u7ba1\u652f\u5b66\u3000Vol\u200546,\u2005No\u20056,\u2005Nov\u20052024\u3000\uff50386<\/li>\n\n\n\n<li>Satoshi Wasamoto\u3001Hisao Imai\u3001Takeshi Tsuda\u3001Yoshiaki Nagai\u3001Takayuki Kishikawa\u3001Akihiro Ono\u3001Ken Masubuchi\u3001Yukihiro Umeda\u3001Yutaka Yamada\u3001Junichi Nakagawa\u3001Takaya Yui\u3001Hirokazu Tniguchi\u3001Kyoichi Kaira\u3001Hiroshi Kagamu\uff0eEfficacy and Safety of First-line Pembrolizumab Plus Platinum and Pemetrexed in Elderly Patients with Non-squamous Non-small-cell Lung Cancer\uff0eInternal Medicine 2024 May1doi: 10.2169\/internalmedicine.3649-24<\/li>\n\n\n\n<li>Satoshi Ano\u3001Norihiro Kikuchi\u3001Shinichiro Okauchi\u3001Takeshi Numata\u3001 Ryota Nakamura\u3001Toshihiro Shiozawa\u3001Hiroko Watanabe\u3001Tomohiro Tamura\u3001Kunihiko Miyazaki\u3001Shigen Hayashi\u3001Takaaki Yamashita\u3001Koichi Kurishima\u3001Masaharu Inagaki\u3001Takayuki Kaburagi\u3001Takeo Endo\u3001Hiroaki Satoh\u3001Nobuyuki Hizawa\uff0eReal Clinical Practice of Combined Atezolizumab Plus Chemotherapy in Patients With Small Cell Lung Cancer\uff0eAnticancer Res. 2024 Jun;44(6):2725-2730<\/li>\n\n\n\n<li>Takashi Hatori\u3001Takeshi Numata\u3001Toshihiro Shiozawa\u3001Manato Taguchi\u3001Hirofumi Sakurai\u3001Tomohiro Tamura\u3001Jun Kanazawa\u3001Hiroaki Tachi\u3001Kyoko Kondo\u3001Kunihiko Miyazaki\u3001Norohiro Kikuchi\u3001Koichi Kurushima\u3001Hiroaki Satoh\u3001Nobuyuki Hizawa\uff0ePrognostic Factors for Patients with small-cell Lung Cancer Treated with Chemoimmunotherapy:A Retrospective Multicenter Study\uff0eCurr Oncol. 2024 Oct 23;31(11):6502-6511<\/li>\n\n\n\n<li>Takeshi Numata\u3001Ryota Nakamura\u3001Toshihiro Shiozawa\u3001Hiroko Watanabe\u3001Shinichiro Okauchi\u3001Gen Ogara\u3001Tomohiro Tamura\u3001Norihiro Kikuchi\u3001Kunihiko Miyazaki\u3001Shigen Hayashi\u3001Takaaki Yamashita\u3001Koichi Kurushima\u3001Masaharu Inagaki\u3001Hiroaki Satoh\u3001Takayuki Kaburagi\u3001Takeo Endo\u3001Nobuyuki Hizawa\uff0e Outcomes of Combined Atezolizumab Plus Chemotherapy in Non-small Cell Lung Cancer Patients in Clinical Practice\uff0eCANCER DIAGNOSIS&amp;PROGNOSIS.2025 Jan 3;5(1):105-114\u00a0\u00a0\u00a0\u00a0<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u540d\u548c\u65e5\u5411\u5b50\u3001\u7530\u6751\u667a\u5b8f\u3001\u5c71\u7530\u8c4a\u3001\u5409\u5ddd\u5f25\u9808\u5b50\u3001\u5c71\u53e3\u662d\u4e09\u90ce\u3001\u6a4b\u672c\u5e7e\u592a\u3001\u93d1\u6728\u5b5d\u4e4b\uff0e\u4e2d\u7b49\u75c7\u306eCOVID-19\u80ba\u708e\u306bKlebsiella pneumonia\u83cc\u8840\u75c7\u3092\u4f75\u767a\u3057\u305f\u5f8c\uff0c\u9593\u8cea\u6027\u80ba\u75be\u60a3\u304c\u7d9a\u767a\u3057\u30b9\u30c6\u30ed\u30a4\u30c9\u7642\u6cd5\u304c\u594f\u52b9\u3057\u305f\uff11\u4f8b\uff0e\u7b2c64\u56de\u65e5\u672c\u547c\u5438\u5668\u5b66\u4f1a\u5b66\u8853\u8b1b\u6f14\u4f1a\u30012024.4.5\uff5e4.7\uff08\u6a2a\u6d5c\uff09<\/li>\n\n\n\n<li>\u7530\u6751\u667a\u5b8f\u3001\u6e21\u908a\u5b89\u7950\u7f8e\u3001\u5927\u4e45\u4fdd\u521d\u7f8e\u3001\u5c71\u7530\u8c4a\u3001\u5409\u5ddd\u5f25\u9808\u5b50\u3001\u5c71\u53e3\u662d\u4e09\u90ce\u3001\u6a4b\u672c\u5e7e\u592a\u3001\u6e21\u9089\u4f91\u5948\u3001\u6589\u85e4\u4ec1\u662d\u3001\u98ef\u5d8b\u9054\u751f\u3001\u93d1\u6728\u5b5d\u4e4b\uff0e\u809d\u69d8\u817a\u764c\u3068\u8003\u3048\u3089\u308c\u8840\u6027\u80f8\u6c34\u306b\u3088\u308a\u6025\u6fc0\u306a\u8ee2\u6a5f\u3092\u305f\u3069\u3063\u305f1\u4f8b\uff0e\u7b2c65\u56de\u65e5\u672c\u80ba\u764c\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0e2024.10.31\uff5e11.2\uff08\u6a2a\u6d5c\uff09<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u4ee4\u548c5\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u8457\u66f8\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Imai H\u3001Wasamoto S\u3001Tsuda T\u3001Nagai Y\u3001Kishikawa T\u3001Masubuchi K\u3001Osaki T\u3001Miura Y\u3001Umeda Y\u3001Ono A\u3001Minemura H\u3001Yamada Y\u3001Nakagawa J\u3001Kozu Y\u3001Taniguchi H\u3001Ohta H\u3001Kasai T\u3001Kaira K\u3001Kagamu H\uff0eUsing the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed\uff0eThorac Cancer. 2023 Jul 19. doi: 10.1111\/1759-7714.15036<\/li>\n\n\n\n<li>Nishihara-Kato F\u3001Imai H\u3001Tsuda T\u3001Wasamoto S\u3001Nagai Y\u3001Kishikawa T\u3001Miura Y\u3001Ono A\u3001Yamada Y\u3001Masubuchi K\u3001Osaki T\u3001Nakagawa J\u3001Umeda Y\u3001Minemura H\u3001Kozu Y\u3001Taniguchi H\u3001Ohta H\u3001Kaira K\u3001Kagamu H\uff0ePrognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel\/Nab-Paclitaxel\uff0eOncology 2024;102(1):30-42. doi: 10.1159\/000533604. Epub 2023 Aug 18<\/li>\n\n\n\n<li>Nawa H\u3001Akine D\u3001Tamura T\u3001Saito K\u3001Kaburagi T\u3001Sasahara T\uff0eDisseminated cryptococcosis in a geriatric man following high-dose systemic steroid therapy for severe COVID-19 pneumonia\uff0eJournal of General and Family Medicine\/2023 Sep 21;24(6):350-351<\/li>\n\n\n\n<li>Okauti S\u3001Ohara G\u3001Shiozawa T\u3001Watanabe H\u3001Numata T\u3001Nakamura R\u3001Tamura T\u3001Norihiro Kikuchi N\u3001Miyazaki K\u3001Hayashi S\u3001Yamashita T\u3001Kurushima K\u3001Inagaki M\u3001Endo T\u3001Ishikawa H\u3001Kaburagi T\u3001Satoh H\u3001Sakamoto T\u3001Hizawa N\uff0eAtezolizumab Monotherapy for Non-small Cell Lung Cancer Patients: An Observational Study in Ibaraki Group (ATTENTION-IBARAKI)\uff0eIn Vivo doi: 10.21873\/invivo.13320.2023 Sep-Oct;37(5):2203-2209<\/li>\n\n\n\n<li>Tamura T\u3001Numata T\u3001Yanai H\u3001Nakamura R\u3001Shiozawa T\u3001Watanabe H\u3001Okauti S\u3001Kikuchi N\u3001Miyazaki K\u3001Hayashi S\u3001Yamashita T\u3001Kurishima K\u3001Inagaki M\u3001Satoh H\u3001Ishikawa H\u3001Kaburagi T\u3001Endo T\u3001Sakamoto T\u3001Hizawa N\uff0eAnticancer Research doi: 10.21873\/anticanres.16652 2023 Oct;43(10):4583-4591<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u4ee4\u548c4\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u8457\u66f8\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Shiozawa T\u3001Numata T\u3001Tamura T\u3001Endo T\u3001 Kaburagi T\u3001Yamamoto Y\u3001Yamada H\u3001Kikuchi N\u3001Saito K\u3001Inagaki M\u3001Kurishima K\u3001Funayama Y\u3001Miyazaki K\u3001Koyama N\u3001Furukawa K\u3001Nakamura H\u3001Kikuchi S\u3001Ichimura H\u3001Sato Y\u3001Sekine I\u3001Satoh H\u3001Hizawa N\uff0ePrognostic Implication of PD-L1 Expression on Osimertinib Treatment for&nbsp;EGFR-mutated Non-small Cell Lung Cancer\uff0eAnticancer Res. 2022 May;42(5):2583-2590. doi: 10.21873\/anticanres.15736. PMID: 35489768<\/li>\n\n\n\n<li>Hiroshima Y\u3001Tamaki Y\u3001Sawada T\u3001Ishida T\u3001Yasue K\u3001Shinoda K\u3001Saito T\u3001Kaburagi T\u3001Kiyoshima M\u3001Okumura T\u3001Sakurai H\uff0eStereotactic Body Radiotherapy for Stage I Lung Cancer With a New Real-time Tumor Tracking System\uff0eAnticancer Res. 2022 Jun;42(6):2989-2995. doi: 10.21873\/anticanres.15782. PMID:&nbsp;35641279<\/li>\n\n\n\n<li>Masubuchi.K\u3001Hisao Imai,\u3001Satoshi Wasamoto,\u3001Takeshi Tsuda ,\u3001Hiroyuki Minemura\u3001Yoshiaki Nagai,\u3001Yutaka Yamada,\u3001Takayuki Kishikawa\u3001 Yukihiro Umeda\u3001Ayako Shiono\u3001Hiroki Takechi\u3001Jun Shiihara\u3001Kyoichi Kaira\u3001Kenya Kanazawa\u3001Hirokazu Taniguchi\u3001Takayuki Kaburagi\u3001 Hiroshi Kagamu\u3001Koichi Minato\uff0ePost-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival\uff0eThorac Cancer. 2022 Sep 5. DOI: 10.1111\/1759-7714.14621 PMID:36062426<\/li>\n\n\n\n<li>Wasamoto.S\u3001Hisao Imai\u3001Takeshi Tsuda\u3001Yoshiaki Nagai\u3001Hiroyuki Minemura\u3001Yutaka Yamada\u3001Yukihiro Umeda\u3001Takayuki Kishikawa\u3001Ayako Shiono\u3001Yuki Kozu\u3001Jun Shiihara\u3001Ou Yamaguchi\u3001Atsuto Mouri\u3001 Kyoichi Kaira\u3001Kenya Kanazawa\u3001Hirokazu Taniguchi\u3001Takayuki Kaburagi\u3001<\/li>\n\n\n\n<li>&nbsp;Koichi Minato\u3001Hiroshi Kagamu\uff0ePretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer\uff0eFront Oncol. 2023 Jan 20;12:1080729. doi: 10.3389\/fonc.2022.1080729 PMID:36741711<\/li>\n\n\n\n<li>Kotake.M\u3001Imai H\u3001Kaira K.\u3001Endoh H\u3001Yamada Y\u3001Kaburagi T\u3001Kiyoshima M\u3001Sugiyama T\u3001Nakamura Y\u3001Kasai T\u3001Matsuguma H\u3001Minemura H\u3001Kanazawa K\u3001Suzuki H\u3001Fujita A\u3001Minato K\uff0eClinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma\uff0eChemotherapy 2022 https:\/\/doi.org\/10.1159\/000524077 PMID:35313303<\/li>\n\n\n\n<li>Shiono A\u3001Hisao Imai\u3001Satoshi Wasamoto\u3001Takeshi Tsuda\u3001Yoshiaki Nagai\u3001Hiroyuki Minemura\u3001Yutaka Yamada\u3001Takayuki Kishikawa\u3001Yukihiro Umeda\u3001Hiroki Takechi\u3001Ou Yamaguchi\u3001Atsuto Mouri\u3001Kyoichi Kaira\u3001 Hirokazu Taniguchi\u3001Koichi Minato\u3001Hiroshi Kagamu\uff0eReal-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer\uff0eCancer Medicine. 2022;00:1\u201311. DOI: 10.1002\/cam4.4938 PMID:35699088<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u7530\u6751\u667a\u5b8f\u3001\u677e\u5009\u3057\u307b\u308a\u3001\u5c71\u7530\u8c4a\u3001\u5409\u5ddd\u5f25\u9808\u5b50\u3001\u5c71\u53e3\u662d\u4e09\u90ce\u3001\u6a4b\u672c\u5e7e\u592a\u3001\u93d1\u6728\u5b5d\u4e4b\uff0e\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u85ac\u6cbb\u7642\u5f8c\u306b\u30c6\u30dd\u30c1\u30cb\u30d6\u304c\u594f\u52b9\u3057\uff0c\u6709\u5bb3\u4e8b\u8c61\u306b\u3088\u308b\u4f11\u85ac\u5f8c\u3082\u594f\u52b9\u3092\u7dad\u6301\u3057\u3066\u3044\u308b\u80ba\u817a\u764c\u306e\uff11\u4f8b\uff0e\u7b2c62\u56de\u65e5\u672c\u547c\u5438\u5668\u5b66\u4f1a\u5b66\u8853\u8b1b\u6f14\u4f1a\u30012022.4.25\uff08\u4eac\u90fd\uff09<\/li>\n\n\n\n<li>\u5c71\u7530\u8c4a\u3001\u93d1\u6728\u5b5d\u4e4b\u3001\u677e\u5009\u3057\u307b\u308a\u3001\u5927\u4e45\u4fdd\u521d\u7f8e\u3001\u7530\u6751\u667a\u5b8f\u3001\u5409\u5ddd\u5f25\u9808\u5b50\u3001\u5c71\u53e3\u662d\u4e09\u90ce\u3001\u6a4b\u672c\u5e7e\u592a\u3001\u9234\u6728\u4e45\u53f2\u3001\u6e05\u5d8b\u8b77\u4e4b\u3001\u96e8\u5bae\u9686\u592a\u3001\u98ef\u5d8b\u9054\u751f\u3001\u6589\u85e4\u4ec1\u662d\uff0e\u5f53\u9662\u306b\u304a\u3051\u308b\u30af\u30e9\u30a4\u30aa\u30d7\u30ed\u30fc\u30d6\u3092\u7528\u3044\u305f\u5c40\u6240\u9ebb\u9154\u4e0b\u80f8\u8154\u93e1\u4e0b\u80f8\u819c\u751f\u691c\u306e\u7d4c\u9a13\u306b\u3064\u3044\u3066\uff0e\u7b2c45\u56de\u65e5\u672c\u547c\u5438\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012022.5.29\uff08\u5c90\u961c\uff09<\/li>\n\n\n\n<li>\u5409\u5ddd\u5f25\u9808\u5b50\u3001\u78ef\u7530\u9054\u4e5f\u3001\u677e\u5009\u3057\u307b\u308a\u3001\u5c71\u7530\u8c4a\u3001\u7530\u6751\u667a\u5b8f\u3001\u5c71\u53e3\u662d\u4e09\u90ce\u3001\u6a4b\u672c\u5e7e\u592a\u3001\u93d1\u6728\u5b5d\u4e4b\uff0e\u30ea\u30d5\u30a1\u30f3\u30d4\u30b7\u30f3\u306b\u3088\u308b\u9593\u8cea\u6027\u80ba\u708e\u6025\u6027\u5897\u60aa\u3001\u30a8\u30bf\u30f3\u30d6\u30c8\u30fc\u30eb\u306b\u3088\u308b\u85ac\u75b9\u3092\u304d\u305f\u3057\u3001\u6cbb\u7642\u306b\u96e3\u6e0b\u3057\u305f\u80baMAC\u75c7\u306e1\u4f8b\uff0e\u7b2c97\u56de\u65e5\u672c\u7d50\u6838 \u30fb\u975e\u7d50\u6838\u6027\u6297\u9178\u83cc\u75c7\u5b66\u4f1a\u7dcf\u4f1a\u30012022.7.3\uff08\u5317\u6d77\u9053\uff09<\/li>\n\n\n\n<li>\u5c71\u7530\u8c4a\u3001\u5c71\u5cb8\u54f2\u4e5f\u3001\u7530\u6751\u667a\u5b8f\u3001\u5409\u5ddd\u5f25\u9808\u5b50\u3001\u5c71\u53e3\u662d\u4e09\u90ce\u3001\u6a4b\u672c\u5e7e\u592a\u3001\u9ad8\u6a4b\u5149\u3001\u95a2\u6839\u5eb7\u6674\u3001\u4e2d\u5ca1\u6d69\u4e8c\u90ce\u3001\u83ca\u6c60\u614e\u4e8c\u3001\u6e05\u5d8b\u8b77\u4e4b\u3001\u93d1\u6728\u5b5d\u4e4b\uff0e\u8328\u57ce\u770c\u306b\u304a\u3051\u308bCOVID-19\u306b\u3088\u308b\u80ba\u764c\u60a3\u8005\u306e\u53d7\u8a3a\u52d5\u5411\u306e\u5f71\u97ff\u306b\u3064\u3044\u3066\uff0e\u7b2c49\u56de\u8328\u57ce\u80ba\u764c\u7814\u7a76\u4f1a\u30012022.9.25\uff08\u8328\u57ce\uff09<\/li>\n\n\n\n<li>\u7530\u6751\u667a\u5b8f\u3001\u5c71\u5cb8\u54f2\u4e5f\u3001\u5927\u4e45\u4fdd\u521d\u7f8e\u3001\u5c71\u7530\u8c4a\u3001\u5409\u5ddd\u5f25\u9808\u5b50\u3001\u5c71\u53e3\u662d\u4e09\u90ce\u3001\u6a4b\u672c\u5e7e\u592a\u3001\u93d1\u6728\u5b5d\u4e4b\uff0eEGFR\u967d\u6027\uff13\u671f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u306b\u5bfe\u3057\u3066\u5316\u5b66\u653e\u5c04\u7dda\u7642\u6cd5\u5f8c\u306b\u30c7\u30e5\u30eb\u30d0\u30eb\u30de\u30d6\u6295\u4e0e\u3092\u884c\u3063\u305f\u75c7\u4f8b\u306b\u95a2\u3059\u308b\u691c\u8a0e\uff0e\u7b2c63\u56de\u65e5\u672c\u80ba\u764c\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012022.12.3\uff08\u798f\u5ca1\uff09<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u4ee4\u548c3\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u8457\u66f8\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Yamada Y\u3001Imai H\u3001Sugiyama T\u3001Minemura H\u3001Kanazawa K\u3001Kasai T\u3001 Minato K\u3001Kaira K\u3001Kaburagi T\uff0eEffectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations\uff0eMedicina (Kaunas)\u30012021 Sep.<\/li>\n\n\n\n<li>Imai H\u3001Kishikawa T\u3001Minemura H\u3001Yamada Y\u3001Ibe T\u3001Mori K\u3001Yamaguchi O\u3001Mouri A\u3001Hamamoto Y\u3001Kanazawa K\u3001Kasai T\u3001Kaira K\u3001Kaburagi T\u3001Minato K\u3001Kobayashi K\u3001Kagamu H\uff0ePost-Progression Survival Influences Overall Survival among Patients with Advanced Non-Small Cell Lung Cancer Undergoing First-Line Pembrolizumab Monotherapy\uff0e Oncology\u3001562-570 &nbsp;2021.9<\/li>\n\n\n\n<li>Imai H\u3001Kishikawa T\u3001Minemura H\u3001Yamada Y\u3001Ibe T\u3001Yamaguchi O\u3001 Mouri A\u3001Hamamoto Y\u3001Kanazawa K\u3001Kasai T\u3001Kaira K\u3001Kaburagi T\u3001 Minato K\u3001Kobayashi K\u3001Kagamu H\uff0ePretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lungcancer\uff0eCancer Med.\u30016971-6984 2021 Oct.\uff0e<\/li>\n\n\n\n<li>Noro R\u3001Igawa S\u3001Bessho A\u3001Hirose T\u3001Shimokawa T\u3001Nakashima M\u3001&nbsp;Minato K\u3001Seki N\u3001Tokito T\u3001Harada T\u3001Sasada S\u3001Miyamoto S\u3001Tanaka Y\u3001Furuya N\u3001Kaburagi T\u3001Hayashi H\u3001Iihara H\u3001Okamoto H\u3001Kubota K.\uff0eA prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632\uff0eLung Cancer\u300149-54 2021 Nov.<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u7530\u6751 \u667a\u5b8f\u3001\u93d1\u6728 \u5b5d\u4e4b\u3001\u5bae\u5d0e \u90a6\u5f66\u3001\u5c71\u7530 \u82f1\u6075\u3001\u8c37\u7530\u8c9d \u6d0b\u5e73\u3001\u8229\u5c71 \u5eb7\u5247\u3001\u9f4a\u85e4 \u548c\u4eba\u3001\u7a32\u57a3 \u96c5\u6625\u3001\u4e2d\u6751 \u535a\u5e78\u3001\u5c0f\u5c71 \u4fe1\u4e4b\u3001\u53e4\u5ddd \u6b23\u4e5f\u3001\u4f50\u85e4 \u6d69\u662d\u3001\u6a9c\u6fa4 \u4f38\u4e4b\uff0eEGFR\u907a\u4f1d\u5b50\u5909\u7570\u967d\u6027\u306e\u9032\u884c\u30fb\u518d\u767a\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u306b\u5bfe\u3057\u3066\u30a2\u30d5\u30a1\u30c1\u30cb\u30d6\u306b\u3088\u308b\u4e00\u6b21\u6cbb\u7642\u3092\u884c\u3063\u305f\u75c7\u4f8b\u306e\u4e88\u5f8c\u306b\u95a2\u3059\u308b\u8328\u57ce\u770c\u5185\u591a\u65bd\u8a2d\u5171\u540c\u7814\u7a76\uff0e\u7b2c61\u56de\u65e5\u672c\u547c\u5438\u5668\u5b66\u4f1a\u5b66\u8853\u8b1b\u6f14\u4f1a\u30012021.4.23\u3000<\/li>\n\n\n\n<li>\u5c71\u7530 \u8c4a\u3001\u93d1\u6728 \u5b5d\u4e4b\u3001\u5927\u4e45\u4fdd \u521d\u7f8e\u3001\u7530\u6751 \u667a\u5b8f\u3001\u5409\u5ddd \u5f25\u9808\u5b50\u3001\u5c71\u53e3 \u662d\u4e09\u90ce\u3001\u6a4b\u672c \u5e7e\u592a\u3001\u9234\u6728 \u4e45\u53f2\u3001\u6e05\u5d8b \u8b77\u4e4b\u3001\u96e8\u5bae \u9686\u592a\uff0eSolemioQUEV\u3092\u7528\u3044\u305f\u6a19\u6e96\u5316\u3055\u308c\u305f\u764c\u6027\u80f8\u819c\u708e\u306e\u5c40\u6240\u9ebb\u9154\u4e0b\u80f8\u8154\u93e1\u691c\u67fb\u6240\u898b\u306e\u8a18\u9332\u306b\u3064\u3044\u3066\uff0e\u7b2c44\u56de\u65e5\u672c\u547c\u5438\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012021.6.24<\/li>\n\n\n\n<li>\u7802\u8fba \u6d69\u5f25\u3001\u7530\u6751 \u667a\u5b8f\u3001\u5927\u4e45\u4fdd \u521d\u7f8e\u3001\u5c71\u7530 \u8c4a\u3001\u5409\u5ddd \u5f25\u9808\u5b50\u3001\u5c71\u53e3 \u662d\u4e09\u90ce\u3001\u6a4b\u672c \u5e7e\u592a\u3001\u93d1\u6728 \u5b5d\u4e4b\uff0e\u80ba\u975e\u7d50\u6838\u6027\u6297\u9178\u83cc\u75c7\u3068\u80ba\u764c\u3092\u5408\u4f75\u3057\u8a3a\u65ad\u306b\u96e3\u6e0b\u3057\u305f\u4e00\u4f8b\uff0e\u7b2c180\u56de\u65e5\u672c\u7d50\u6838\u30fb\u975e\u7d50\u6838\u6027\u6297\u9178\u83cc\u75c7\u5b66\u4f1a\u95a2\u6771\u652f\u90e8\u5b66\u4f1a \u7b2c246\u56de\u65e5\u672c\u547c\u5438\u5668\u5b66\u4f1a\u95a2\u6771\u5730\u65b9\u4f1a \u5408\u540c\u5b66\u4f1a\u30012021.9.26<\/li>\n\n\n\n<li>\u7530\u6751 \u667a\u5b8f\u3001\u93d1\u6728 \u5b5d\u4e4b\u3001\u6817\u5cf6 \u6d69\u4e00\u3001\u77f3\u5ddd \u535a\u4e00\u3001\u6cbc\u7530 \u5cb3\u58eb\u3001\u9060\u85e4 \u5065\u592b\u3001\u5869\u6fa4 \u5229\u535a\u3001\u6a9c\u6fa4 \u4f38\u4e4b\u3001\u5c71\u672c \u7950\u4ecb\u3001\u5e02\u6751 \u79c0\u592b\u3001\u9f4a\u85e4 \u548c\u4eba\u3001\u5bae\u5d0e \u90a6\u5f66\u3001\u5c71\u7530 \u82f1\u6075\u3001\u4e2d\u6751 \u535a\u5e78\u3001\u53e4\u5ddd \u6b23\u4e5f\u3001\u83ca\u6c60 \u6559\u5927\uff0e\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u4e00\u6b21\u6cbb\u7642\u5f8c\u306b\u4ed6\u306eEGFR-TKI\u3092\u6295\u4e0e\u3057\u305fEGFR \u967d\u6027\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u306e\u691c\u8a0e\uff0e\u7b2c62\u56de\u65e5\u672c\u80ba\u764c\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012021.11.27<\/li>\n\n\n\n<li>\u677e\u5009 \u3057\u307b\u308a\u3001\u5c71\u7530 \u8c4a\u3001\u7530\u6751 \u667a\u5b8f\u3001\u5409\u5ddd \u5f25\u9808\u5b50\u3001\u5c71\u53e3 \u662d\u4e09\u90ce\u3001\u6e05\u5d8b \u8b77\u4e4b\u3001\u9234\u6728 \u4e45\u53f2\u3001\u6589\u85e4 \u4ec1\u662d\u3001\u93d1\u6728 \u5b5d\u4e4b\uff0e\u8853\u524d\u306b\u611f\u67d3\u6027\u75be\u60a3\u3068\u306e\u9451\u5225\u304c\u56f0\u96e3\u3067\u3042\u3063\u305f\u80ba\u6241\u5e73\u4e0a\u76ae\u764c\u306e\u4e00\u4f8b\uff0e\u7b2c181\u56de\u65e5\u672c\u7d50\u6838\u30fb\u975e\u7d50\u6838\u6027\u6297\u9178\u83cc\u75c7\u5b66\u4f1a\u95a2\u6771\u652f\u90e8\u5b66\u4f1a \u7b2c248\u56de\u65e5\u672c\u547c\u5438\u5668\u5b66\u4f1a\u95a2\u6771\u5730\u65b9\u4f1a \u5408\u540c\u5b66\u4f1a\u30012022.2.26<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u4ee4\u548c\uff12\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u8457\u66f8\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Yutaka Yamada\u3001Tomohiro Tamura\u3001Yusuke Yammoto\u3001Hideo Ichimura\u3001Kenji Hayashihara\u3001Takefumi Saito\u3001Hideyasu Yamada\u3001Takeo Endo\u3001 Ryota Nakamura\u3001Yoshihisa Inage\u3001Hiroaki Satoh\u3001Kesato Iguchi\u3001KazuoSaito\u3001Masaharu Inagaki\u3001Norihiro Kikuchi\u3001Koichi Kurishima\u3001Hiroichi Ishikawa\u3001Mitsuaki Sakai\u3001Koichi Kamiyama\u3001Toshihiro Shiozawa\u3001Nobuyuki Hizawa\u3001Ikuo Sekine\u3001Yukio Sato\u3001Yasunori Funayama\u3001Kunihiko Miyazaki\u3001Takahide Kodama\u3001Shigen Hayashi\u3001Akihiro Nomura\u3001Hiroyuki Nakamura\u3001Kinya Furukawa\u3001Takaaki Yamashita\u3001Hatsumi Okubo\u3001Hisashi Suzuki\u3001Moriyuki Kiyoshima\u3001Takayuki Kaburagi\uff0eTreatment of Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutation in Clinical Practice\uff0eAnticancer Research\u30015757-5764 2020.10.<\/li>\n\n\n\n<li>Hisao Imai\u3001Hiroyuki Minemura\u3001Takayuki Kishikawa\u3001Yutaka Yamada\u3001 Kensuke Suzuki\u3001Yukihiro Umeda\u3001Satoshi Wasamoto\u3001Norimitsu Kasahara\u3001Shinichi Ishihara\u3001Ou Yamaguchi\u3001Ichiro Naruse\u3001Junji Uchino\u3001Keita Mori\u3001Kenya Kanazawa\u3001Yoko shibata\u3001Takashi Kasai\u3001Takayuki Kaburagi\u3001Kyoichi Kaira\u3001Koichi Minato\uff0eEfficacy and safety of S-1 monotherapy in previously treated elderly patients (aged\u226775years) with non-small cell lung cancer: A retrospective analysis\uff0eThoracic Cancer\u30012020.<\/li>\n\n\n\n<li> Kasai T\u3001Kiyoshi Mori\u3001Kazuma Kishi\u3001Takayuki Kaburagi\u3001Yukio Hosomi\u3001 Hisao Imai\u3001Yutaka Yamada\u3001Makiko Yomota\u3001Syuhei Moriguchi\u3001Masahiro Seike\u3001Koichi Minato\u3001Akihiko Gemma &amp; for The Tokyo Cooperative Oncology Group\uff0eA Phase I and Extension study of S-1 and Carboplatin for Previously Untreated Patients Aged 75 years or more with Advanced Non-Small Cell Lung Cancer -TCOG 1101\uff0eInternational Journal of Clinical Oncology 25,(2020)\u3001867\u2013875 2020.<\/li>\n\n\n\n<li>Numata T\u3001TAKEO ENDO,\u3001HIDETOSHI YANAI\u3001 KYOKO OTA\u3001YUSUKE YAMAMOTO\u3001KEI SHIMIZU,\u3001HIDEYASU YAMADA\u3001KENJI HAYASHIHARA\u3001SHINICHIRO OKAUCHI\u3001HIROAKI SATOH\u3001YUTAKA YAMADA\u3001TOMOHIRO TAMURA\u3001KAZUTO SAITO\u3001NORIHIRO KIKUCHI\u3001KOICHI KURISHIMA\uff0eSerum CEA and CYFRA Levels in ALK-rearrangedNSCLC Patients: orrelation With Distant Metastasis\uff0ein vivo 34: (2020)doi:10.21873\/invivo.12013\u30012095-2100 2020.<\/li>\n\n\n\n<li>Okauchi S\u3001Numata T\u3001Nawa T\u3001Ichimura H\u3001Saito T\u3001Hayashihara K\u3001 Yamada H\u3001Satoh H\u3001Endo T\u3001Inage Y\u3001Kaburagi T\u3001Kiyoshima M\u3001Yamada Y\u3001Tamura T\u3001Saito K\u3001Inagaki M\u3001Hizawa N\u3001Sato Y\u3001Shiozawa T\u3001Sekine I\u3001Ishikawa H\u3001Kurihima K\u3001Sakai M\u3001Kamiyama K\u3001Kimura M\u3001Kikuchi N\u3001Nakamura H\u3001Furukawa K\u3001Kodama T\u3001Miyazaki K\u3001Yamashita T\u3001Hayashi S\u3001Funayama Y\u3001Nomura A\uff0eReal Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study\uff0eAnticancer research 2020 Feb; Vol. 40 (2)\u3001957-964 2020.<\/li>\n\n\n\n<li> Minemura H\u3001Hiroshi Moriya\u3001Hisao Imai\u3001Tomohide Sugiyama\u3001Yutaka Yamada\u3001Mitsunori Higuchi\u3001Kyoichi Kaira\u3001Yuki Ozaki\u3001Kenya Kanazawa Hiroshi Yokouchi\u3001Takashi Kasai\u3001Takayuki Kaburagi\u3001Hiroyuki Suzuki\u3001 Koichi Minato\u3001Yoko Shibata.Thorac Cancer\u30012020.<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u5927\u4e45\u4fdd \u521d\u7f8e\u3001\u93d1\u6728 \u5b5d\u4e4b\u3001\u677e\u5009 \u3057\u307b\u308a\u3001\u5c71\u7530 \u8c4a\u3001\u7530\u6751 \u667a\u5b8f\u3001\u5409\u5ddd \u5f25\u9808\u5b50\u3001\u5c71\u53e3 \u662d\u4e09\u90ce\u3001\u6a4b\u672c \u5e7e\u592a\u3001\u9234\u6728 \u4e45\u53f2\u3001\u6e05\u5d8b \u8b77\u4e4b\u3001\u96e8\u5bae \u9686\u592a\uff0e\u5f53\u9662\u306b\u304a\u3051\u308b\u5185\u8996\u93e1\u7684\u6c17\u9053\u7570\u7269\u9664\u53bb\u75c7\u4f8b\u306e\u691c\u8a0e\uff0e\u7b2c 43 \u56de\u65e5\u672c\u547c\u5438\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012020.6.<\/li>\n\n\n\n<li>\u5c71\u7530 \u8c4a\u3001\u897f\u91ce \u9855\u543e\u3001\u5927\u4e45\u4fdd \u521d\u7f8e\u3001\u7530\u6751 \u667a\u5b8f\u3001\u5409\u5ddd \u5f25\u9808\u5b50\u3001\u5c71\u53e3 \u662d\u4e09\u90ce\u3001\u6a4b\u672c \u5e7e\u592a\u3001\u93d1\u6728 \u5b5d\u4e4b\uff0e\u80c3\u764c\u518d\u767a\u6642\u306b\u8a3a\u65ad\u3055\u308c\u305f\u80ba\u7d50\u6838\u306e 1 \u4f8b\uff0e\u7b2c 178 \u56de\u65e5\u672c\u7d50\u6838\u30fb\u975e\u7d50\u6838\u6027\u6297\u9178\u83cc\u75c7\u5b66\u4f1a\u95a2\u6771\u652f\u90e8\u5b66\u4f1a \u7b2c 241 \u56de\u65e5\u672c\u547c\u5438\u5668\u5b66\u4f1a\u95a2\u6771\u5730\u65b9\u4f1a \u5408\u540c\u5b66\u4f1a\u30012020.9.<\/li>\n\n\n\n<li> Rintaro Noro\u3001Satoshi Igawa\u3001Akihiro Bessho\u3001Takashi Hirose\u3001Tsuneo Shimokawa\u3001Masanao Nakashima\u3001Koichi Minato\u3001Nobuhiko Seki\u3001Takaaki Tokito\u3001ToshiyukiHarada\u3001Shinji Sasada\u3001Shingo Miyamoto\u3001Yosuke Tanaka\u3001Naoki Furuya\u3001TakayukiKaburagi\u3001Hideki Hayashi\u3001Hirotoshi Iihara\u3001Hiroaki Okamoto\u3001Kaoru Kubota\uff0eA prospective\u3001phase\u2161trial of low-dose afatinib monotherapy for patienys with EGFR\u3001mutation-positive\u3001non-small cell lung cancer(TORG1632)\uff0eESMO Virtual Congress2020\u6b27\u5dde\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u30012020.9.<\/li>\n\n\n\n<li>Tetsuro Kondo\u3001Takashi Kasai\u3001Kiyoshi Mori\u3001Haruhiro Saito\u3001Kazuo Nishikawa\u3001Satoshi Otsu\u3001obuhiko Seki\u3001Yasuko Ichikawa\u3001Akihiro Bessho\u3001Hiroshi Tanaka\u3001Hiroyuki Yamaguchi\u3001Takayuki Kaburagi\u3001Kenya Kanazawa\u3001Yuko Komase\u3001Koichi Minato\u3001Yuki Misumi\u3001Ryotaro Morinaga\u3001 Keita Mori\u3001Junya Ohtake\u3001Hiroaki Okamoto\uff0eA Randomized Phase\u2161Trial of Pemetrexed Plus Bevacizumab vs. Pemetrexed Alone after the Treatment with Cisplatin\u3001 Pemetrexed and Bevacizumab in Untreated Advanced NonSmall Cell Lung Cancer(TORG1321)\uff0eESMO Virtual Congress2020 \u6b27\u5dde\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u30012020.9.<\/li>\n\n\n\n<li>\u7530\u6751 \u667a\u5b8f\u3001\u677e\u5009 \u3057\u307b\u308a\u3001\u5c71\u7530 \u8c4a\u3001\u5409\u5ddd \u5f25\u9808\u5b50\u3001\u5c71\u53e3 \u662d\u4e09\u90ce\u3001\u9234\u6728 \u4e45\u53f2\u3001\u6a4b\u672c \u5e7e\u592a\u3001\u6e05\u5d8b \u8b77\u4e4b\u3001\u93d1\u6728 \u5b5d\u4e4b\u3001\u4f50\u85e4 \u6d69\u662d\u3001\u6a9c\u6fa4 \u4f38\u4e4b\uff0e\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u85ac\u6295\u4e0e\u5f8c\u306b\u80c6\u7ba1\u708e\u3092\u767a\u75c7\u3057\u305f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u75c7\u4f8b\u306e\u691c\u8a0e\uff0e\u7b2c 60 \u56de\u65e5\u672c\u547c\u5438\u5668\u5b66\u4f1a\u5b66\u8853\u8b1b\u6f14\u4f1a\u30012020.9.<\/li>\n\n\n\n<li>\u56db\u65b9\u7530 \u771f\u7d00\u5b50\u3001\u7b20\u4e95 \u5c1a\u3001\u68ee \u6e05\u5fd7\u3001\u5cb8 \u4e00\u99ac\u3001\u93d1\u6728 \u5b5d\u4e4b\u3001\u7d30\u898b \u5e78\u751f\u3001\u4eca\u4e95 \u4e45\u96c4\u3001\u5c71\u7530 \u8c4a\u3001\u6e05\u5bb6 \u6b63\u535a\u3001\u68ee\u53e3 \u4fee\u5e73\u3001\u6e4a \u6d69\u4e00\u3001\u5f26\u9593 \u662d\u5f66\uff0e75 \u6b73\u4ee5\u4e0a\u306e\u672a\u6cbb\u7642\u9032\u884c\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u306b\u5bfe\u3059\u308b S-1+\u30ab\u30eb\u30dc\u30d7\u30e9\u30c1\u30f3\u7642\u6cd5\u306e\u7b2c\u2160\u76f8\u81e8\u5e8a\u8a66\u9a13\uff0e\u7b2c 60 \u56de\u65e5\u672c\u547c\u5438\u5668\u5b66\u4f1a\u5b66\u8853\u8b1b\u6f14\u4f1a\u30012020.9.<\/li>\n\n\n\n<li> \u677e\u7530 \u5cf0\u53f2\u3001\u5869\u6fa4 \u5229\u535a\u3001\u4e2d\u6fa4 \u5065\u4ecb\u3001\u5bae\ufa11 \u90a6\u5f66\u3001\u7530\u6751 \u667a\u5b8f\u3001\u93d1\u6728 \u5b5d\u4e4b\u3001\u95a2\u6839 \u90c1\u592b\u3001\u4f50\u85e4 \u6d69\u662d\u3001\u6a9c\u6fa4 \u4f38\u4e4b\uff0e\u9032\u884c\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u306b\u5bfe\u3059\u308b\u30c9\u30bb\u30bf\u30ad\u30bb\u30eb+\u30e9\u30e0\u30b7\u30eb\u30de\u30d6\u7642\u6cd5\u306e\u89e3\u6790\uff0e\u7b2c 60 \u56de \u65e5\u672c\u547c\u5438\u5668\u5b66\u4f1a\u5b66\u8853\u8b1b\u6f14\u4f1a\u30012020.9.<\/li>\n\n\n\n<li> \u677e\u7530 \u5cf0\u53f2\u3001\u5869\u6fa4 \u5229\u535a\u3001\u4e2d\u6fa4 \u5065\u4ecb\u3001\u5bae\ufa11 \u90a6\u5f66\u3001\u7530\u6751 \u667a\u5b8f\u3001\u93d1\u6728 \u5b5d\u4e4b\u3001\u95a2\u6839 \u90c1\u592b\u3001\u4f50\u85e4 \u6d69\u662d\u3001\u6a9c\u6fa4 \u4f38\u4e4b\uff0e\u9032\u884c\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u306b\u5bfe\u3059\u308b DOC+Ram \u7642\u6cd5\u306e\u691c\u8a0e\uff0e\u7b2c 60 \u56de\u65e5\u672c\u547c\u5438\u5668\u5b66\u4f1a\u5b66\u8853\u8b1b\u6f14\u4f1a\u30012020.9.<\/li>\n\n\n\n<li>\u5cf0\u6751 \u6d69\u4e4b\u3001\u4eca\u6751 \u4e45\u96c4\u3001\u5cb8\u5ddd \u5b5d\u4e4b\u3001\u5c71\u7530 \u8c4a\u3001\u9234\u6728 \u5065\u4ecb\u3001\u6885\u7530 \u5e78\u5bdb\u3001\u548c\u4f50\u672c \u8aed\u3001\u7b20\u539f \u793c\u5149\u3001\u77f3\u539f \u771f\u4e00\u3001\u5c71\u53e3 \u592e\u3001\u6210\u6e05 \u4e00\u90ce\u3001\u5185\u91ce \u9806\u6cbb\u3001\u76db \u5553\u592a\u3001\u91d1\u6ca2 \u8ce2\u4e5f\u3001\u67f4\u7530 \u967d\u5149\u3001\u7b20\u4e95 \u5c1a\u3001\u93d1\u6728 \u5b5d\u4e4b\u3001\u89e3\u826f \u606d\u4e00\u3001\u6e4a \u6d69\u4e00\uff0e\u9ad8\u9f62\u8005\u65e2\u6cbb\u7642\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u306b\u5bfe\u3059\u308b S-1 \u306e\u52b9\u679c\u304a\u3088\u3073\u5b89\u5168\u6027\u306e\u691c\u8a0e\uff0e\u7b2c 61 \u56de\u65e5\u672c\u80ba\u764c\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012020.11.<\/li>\n\n\n\n<li>\u7530\u6751 \u667a\u5b8f\u3001\u5927\u4e45\u4fdd \u521d\u7f8e\u3001\u5c71\u7530 \u8c4a\u3001\u5409\u5ddd \u5f25\u9808\u5b50\u3001\u5c71\u53e3 \u662d\u4e09\u90ce\u3001\u6a4b\u672c \u5e7e\u592a\u3001\u93d1\u6728 \u5b5d\u4e4b\u3001\u9234\u6728 \u4e45\u53f2\u3001\u6e05\u5d8b \u8b77\u4e4b\u3001\u6589\u85e4 \u4ec1\u662d\u3001\u98ef\u5d8b \u9054\u751f\u3001\u4f50\u85e4 \u6d69\u662d\u3001\u6a9c\u6fa4 \u4f38\u4e4b\uff0e\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u85ac\u4f75\u7528\u5316\u5b66\u7642\u6cd5\u306b\u5bfe\u3059\u308b\u6cbb\u7642\u53cd\u5fdc\u6027\u304c\u90e8\u4f4d\u306b\u3088\u308a\u5927\u304d\u304f\u7570\u306a\u3063\u305f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u306e\uff11\u4f8b\uff0e\u7b2c 61 \u56de\u65e5\u672c\u80ba\u764c\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012020.11.<\/li>\n\n\n\n<li>\u5c71\u7530 \u8c4a\u3001\u93d1\u6728 \u5b5d\u4e4b\u3001\u5927\u4e45\u4fdd \u521d\u7f8e\u3001\u7530\u6751 \u667a\u5b8f\u3001\u5409\u5ddd \u5f25\u9808\u5b50\u3001\u5c71\u53e3 \u662d\u4e09\u90ce\u3001\u6a4b\u672c \u5e7e\u592a\u3001\u9234\u6728 \u4e45\u53f2\u3001\u6e05\u5d8b \u8b77\u4e4b\u3001\u96e8\u5bae \u9686\u592a\uff0e\u6a19\u6e96\u5316\u3055\u308c\u305f\u764c\u6027\u80f8\u819c\u708e\u306e\u5c40\u6240\u9ebb\u9154\u4e0b\u80f8\u8154\u93e1\u691c\u67fb\u6240\u898b\u306e\u8a18\u9332\u306b\u3064\u3044\u3066\uff0e\u7b2c 61 \u56de\u65e5\u672c\u80ba\u764c\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012020.11.<\/li>\n\n\n\n<li>\u5bae\ufa11 \u90a6\u5f66\u3001\u6cbc\u7530 \u5cb3\u58eb\u3001\u9060\u85e4 \u5065\u592b\u3001\u5c71\u672c \u7950\u4ecb\u3001\u5c71\u7530 \u82f1\u6075\u3001\u6797\u539f \u8ce2\u6cbb\u3001\u5ca1\u5185 \u771e\u4e00\u90ce\u3001\u4f50\u85e4 \u6d69\u662d\u3001\u5c71\u7530 \u8c4a\u3001\u7530\u6751 \u667a\u5b8f\u3001\u9f4a\u85e4 \u548c\u4eba\u3001\u83ca\u6c60 \u6559\u5927\u3001\u6817\u5cf6 \u6d69\u4e00\u3001\u77f3\u5ddd \u535a\u4e00\u3001\u6e21\u908a \u88d5\u5b50\u3001\u5869\u6fa4 \u5229\u535a\u3001\u8229\u5c71 \u5eb7\u5247\u3001\u6797 \u58eb\u5143\u3001\u4e2d\u6751 \u535a\u5e78\u3001\u5c71\u4e0b \u9ad8\u660e\uff0e\u9ad8\u9f62(65 \u6b73\u4ee5\u4e0a)\u306e ALK \u878d\u5408\u907a\u4f1d\u5b50\u967d\u6027\u75c7\u4f8b\u306e\u691c\u8a0e\uff0e\u7b2c 61 \u56de\u65e5\u672c\u80ba\u764c\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012020.11.<\/li>\n\n\n\n<li>\u7530\u6751 \u667a\u5b8f\u3001\u5c71\u7530 \u8c4a\u3001\u5409\u5ddd \u5f25\u9808\u5b50\u3001\u5c71\u53e3 \u662d\u4e09\u90ce\u3001\u9234\u6728 \u4e45\u53f2\u3001\u6a4b\u672c \u5e7e\u592a\u3001\u6e05\u5d8b \u8b77\u4e4b\u3001\u93d1\u6728 \u5b5d\u4e4b\u3001\u4f50\u85e4 \u6d69\u662d\u3001\u6a9c\u6fa4 \u4f38\u4e4b\uff0e\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u306b\u7d9a\u3044\u3066\u30a2\u30d5\u30a1\u30c1\u30cb\u30d6\u3092\u6295\u4e0e\u3057\u305f EGFR\u967d\u6027\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u306e\u691c\u8a0e\uff0e\u7b2c 18 \u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012021.2.<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u4ee4\u548c\u5143\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u8457\u66f8\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u6a4b\u672c\u5e7e\u592a, \u93d1\u6728\u5b5d\u4e4b, \u5c0f\u5cf6 \u5bdb, \u67f3\u5ddd \u5fb9\uff1a\u6b6f\u79d1\u533b\u9662\u306e\u305f\u3081\u306e\u5185\u79d1\u5b66\u8b1b\u5ea7 \u5168\u8eab\u7ba1\u7406\u30fb\u5168\u8eab\u75be\u60a3\u3092\u898b\u636e \u3048\u305f\u88dc\u7db4\u6cbb\u7642\u306e\u30b9\u30b9\u30e1 \u6b6f\u79d1\u533b\u9662\u306b\u304a\u3051\u308b\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u75c7\u5bfe\u7b56 \u60a3\u8005\u3001\u30b9\u30bf\u30c3\u30d5\u3001\u305d\u3057 \u3066\u81ea\u9662\u3092\u5b88\u308b\u305f\u3081\u306b\u77e5\u3063\u3066\u304a\u304f\u3079\u304d\u3053\u3068\u30fb\u53d6\u308a\u7d44\u3080\u3079\u304d\u3053\u3068\uff0e\u88dc\u7db4\u81e8\u5e8a(0018-6341)53 \u5dfb 3 \u53f7\u3001 231-242\u30012020\uff0e05<\/li>\n<\/ol>\n\n\n\n<ol start=\"2\" class=\"wp-block-list\">\n<li>Ito H, Ishibashi S, Kaburagi T\uff0eMondor&#8217;s Disease\uff0eInternalmedicine\u30012018-2024\u30012019\uff0e6<\/li>\n\n\n\n<li>\u77f3\u4e95\u82b3\u6a39, \u93d1\u6728\u5b5d\u4e4b, \u77f3\u4e95 \u8061, \u5ca1\u90e8\u548c\u502b, \u7b39\u7530\u771f\u6ecb, \u6b66\u653f\u8061\u6d69, \u4e2d\u5cf6\u5d07\u88d5, \u6d45\u91ce\u6587\u7950, \u65e5\u672c\u547c\u5438\u5668\u5185 \u8996\u93e1\u5b66\u4f1a\u5c40\u6240\u9ebb\u9154\u4e0b\u80f8\u8154\u93e1\u8a3a\u65ad\u30ef\u30fc\u30ad\u30f3\u30b0\u30b0\u30eb\u30fc\u30d7\uff0e\u5c40\u6240\u9ebb\u9154\u4e0b\u80f8\u8154\u93e1\u6240\u898b\u8a18\u8f09\u65b9\u6cd5\u306e\u6a19\u6e96\u5316\uff0e\u6c17 \u7ba1\u652f\u5b66(0287-2137)41 \u5dfb 4 \u53f7\u3001337-349\u30012019.07<\/li>\n\n\n\n<li>\u5927\u4e45\u4fdd\u521d\u7f8e, \u9ad8\u6728\u96c4\u57fa, \u7530\u6751\u667a\u5b8f, \u5c71\u53e3\u662d\u4e09\u90ce, \u6a4b\u672c\u5e7e\u592a, \u93d1\u6728\u5b5d\u4e4b\uff1aX \u7dda\u5199\u771f\u304c\u70ad\u9178\u30e9\u30f3\u30bf\u30f3\u6c34\u548c \u7269\u30c1\u30e5\u30a2\u30d6\u30eb\u9320\u306e\u8aa4\u56a5\u306e\u8a3a\u65ad\u306b\u6709\u7528\u3067\u3042\u3063\u305f 1 \u4f8b\uff0e\u65e5\u672c\u547c\u5438\u5668\u5b66\u4f1a\u8a8c(2186-5876)8 \u5dfb 4 \u53f7\u3001302- 305\u30012019.07<\/li>\n\n\n\n<li>Okauchi S, Numata T, Nawa T, Ichimura H, Saito T, Hayashihara K, Yamada H, Satoh H, Endo T, Inage Y, Kaburagi T, Kiyoshima M, Yamada Y, Tamura T, Saito K, Inagaki M, Hizawa N, Sato Y, Shiozawa T, Sekine I, Ishikawa H, kurihima K, Sakai M, Kamiyama K, Kimura M, Kikuchi N, Nakamura H, Furukawa K, Kodama T, Miyazaki K, Yamashita T, Hayashi S, Funayama Y, Nomura A\uff0eReal Clinical Practice in ALK-rearranged NSCLC Patients:A Retrospective Observational Study\uff0eAnticancer Res\u3001957-964\u30012020\uff0e2<\/li>\n\n\n\n<li>Kasai T, Takashi Kasai, Kiyoshi Mori, Kazuma Kishi, Takayuki Kaburagi, Yukio Hosomi, Hisao Imai, Yutaka Yamada, Makiko Yomota, Syuhei Moriguchi, Masahiro Seike, Koichi Minato, Akihiko Gemma &amp; for The Tokyo Cooperative Oncology Group\uff0eA Phase I and Extension study of S-1 and Carboplatin for Previously Untreated Patients Aged 75 years or more with Advanced NonSmall Cell Lung Cancer -TCOG 1101\uff0eInternational Journal of Clinical Oncology 25\u3001867-875\u30012020.2<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u4fdd\u5742\u4fca\u8cb4\u3001\u98ef\u5cf6\u4e00\u98db\u3001 \u5c71\u7530 \u8c4a\u3001 \u7530\u6751\u667a\u5b8f\u3001\u5409\u5ddd\u5f25\u9808\u5b50\u3001\u5c71\u53e3\u662d\u4e09\u90ce\u3001\u6a4b\u672c\u5e7e\u592a\u3001\u93d1\u6728\u5b5d\u4e4b\u3001\u98ef \u5d8b\u9054\u592b\u3001\u85e4\u5c3e\u9ad8\u884c\uff0e\u5256\u691c\u3067\u3073\u307e\u3093\u6027\u5927\u7d30\u80de\u578b B \u7d30\u80de\u30ea\u30f3\u30d1\u816b\u3068\u80ba\u764c\u306e\u5408\u4f75\u304c\u660e\u3089\u304b\u3068\u306a\u3063\u305f 1 \u4f8b\uff0e \u65e5\u672c\u5185\u79d1\u5b66\u4f1a\u7b2c 60 \u56de\u95a2\u6771\u5730\u65b9\u4f1a\u30012019\uff0e5\uff08\u6771\u4eac\uff09<\/li>\n<\/ol>\n\n\n\n<ol start=\"2\" class=\"wp-block-list\">\n<li>Y. Yamada, H. Imai, H. Minemura, T. Sugiyama, K. Kaira, K. Kanazawa, T. Kasai, K. Minato, T. Kaburagi\uff0eEfficacy and safety of EGFR-TKI Rechallenge treatment in elderly patients with advances non-small-cell lung cancer harboring sensitive EGFR mutations\uff0e20th WCLC\u3001 2019\uff0e9\uff08Barcelona SPAIN\uff09<\/li>\n\n\n\n<li>\u83c5\u91ce\u54f2\u5e73\u3001\u7b20\u4e95 \u5c1a\u3001\u68ee \u6e05\u5fd7\u3001\u5cb8 \u4e00\u99ac\u3001\u93d1\u6728\u5b5d\u4e4b\u3001\u56db\u65b9\u7530\u771f\u7d00\u5b50\u3001\u4eca\u4e95\u4e45\u96c4\u3001\u5c71\u7530 \u8c4a\u3001\u7d30\u898b\u5e78\u751f\u3001 \u68ee\u53e3\u4fee\u5e73\u3001 \u6e4a \u6d69\u4e00\u3001 \u5f26\u9593\u662d\u5f66\uff0e75 \u6b73\u4ee5\u4e0a\u306e\u672a\u6cbb\u7642\u9032\u884c\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u306b\u5bfe\u3059\u308b S-1+\u30ab\u30eb\u30dc \u30d7\u30e9\u30c1\u30f3\u7642\u6cd5\u306e\u7b2c 1 \u76f8\u81e8\u5e8a\u8a66\u9a13(\u82f1\u8a9e)\uff0e\u7b2c 57 \u56de\u65e5\u672c\u764c\u6cbb\u7642\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012019\uff08\u798f\u5ca1\uff09<\/li>\n\n\n\n<li>\u7be0\u539f \u60a0\u3001\u77f3\u4e95\u4f38\u5c1a\u3001\u83ca\u6c60 \u99a8\u3001\u6d77\u8001\u6839\u9ebb\u7406\u3001\u5c71\u53e3\u662d\u4e09\u90ce\uff0e\u8d85\u6025\u6027\u671f\u304b\u3089\u306e\u547c\u5438\u30b1\u30a2\u30b5\u30dd\u30fc\u30c8\u30c1\u30fc\u30e0 \u4ecb\u5165\u306e\u53d6\u308a\u7d44\u307f\uff5e\u7406\u5b66\u7642\u6cd5\u4ecb\u5165\u4f8b\u3092\u632f\u308a\u8fd4\u3063\u3066\uff5e\uff0e\u7b2c 58 \u56de\u81ea\u6cbb\u4f53\u75c5\u9662\u5b66\u4f1a\u3001\u7b2c 58 \u56de\u81ea\u6cbb\u4f53\u75c5\u9662\u5b66 \u4f1a\u30012019\uff0e10\uff08\u5fb3\u5cf6\uff09<\/li>\n\n\n\n<li>\u7530\u6751\u667a\u5b8f\u3001\u5e02\u6751\u79c0\u592b\u3001\u4f50\u85e4\u6d69\u662d\u3001\u6e05\u5d8b\u8b77\u4e4b\u3001\u5869\u6fa4\u5229\u535a\u3001\u6817\u5cf6\u6d69\u4e00\u3001\u8229\u5c71\u5eb7\u5247\u3001\u5150\u7389\u5b5d\u79c0\u3001\u95a2\u6839\u90c1\u592b\uff0eEGFR uncommon mutation \u3092\u6709\u3059\u308b\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u306e\u6cbb\u7642\u30fb\u4e88\u5f8c\u306b\u95a2\u3059\u308b\u8328\u57ce\u770c\u5185\u591a\u65bd\u8a2d\u8abf\u67fb \u7814\u7a76\uff0e\u7b2c 60 \u56de\u65e5\u672c\u80ba\u764c\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012019\uff0e12\uff08\u5927\u962a\uff09<\/li>\n\n\n\n<li>\u5c71\u7530 \u8c4a\u3001\u6797\u539f\u8ce2\u6cbb\u3001\u7a32\u6bdb\u82b3\u6c38\u3001\u7a32\u57a3\u96c5\u6625\u3001\u5c0f\u6797\u5c1a\u5bdb\u3001\u795e\u5c71\u5e78\u4e00\u3001\u53e4\u5ddd\u6b23\u4e5f\u3001\u5c71\u4e0b\u9ad8\u660e\u3001\u6797 \u58eb\u5143\u3001\u4f50\u85e4\u6d69\u662d\uff0eEGFR uncommon mutation \u3092\u6709\u3059\u308b\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u8a3a\u7642\u306b\u95a2\u3059\u308b\u8328\u57ce\u770c\u5185\u591a\u65bd\u8a2d\u8abf\u67fb\u7814\u7a76.\u7b2c 60 \u56de\u65e5\u672c\u80ba\u764c\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012019\uff0e12\uff08\u5927\u962a\uff09<\/li>\n\n\n\n<li>\u5c71\u7530 \u8c4a\u3001\u7b20\u4e95 \u5c1a\u3001 \u5cb8 \u4e00\u99ac\u3001 \u83c5\u91ce\u54f2\u5e73\u3001 \u56db\u65b9\u7530\u771f\u7d00\u5b50\u3001\u4eca\u4e95\u4e45\u96c4\u3001 \u7d30\u898b\u5e78\u751f\u3001 \u68ee\u53e3\u4fee\u5e73\u3001\u6e4a \u6d69\u4e00\u3001\u68ee \u6e05\u5fd7\u3001\u5f26\u9593\u662d\u5f66\u3001\u93d1\u6728\u5b5d\u4e4b\uff0e75 \u6b73\u4ee5\u4e0a\u306e\u672a\u6cbb\u7642\u9032\u884c\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u306b\u5bfe\u3059\u308b S-1+\u30ab\u30eb\u30dc\u30d7 \u30e9\u30c1\u30f3\u7642\u6cd5\u306e\u7b2c I \u76f8\u81e8\u5e8a\u8a66\u9a13\uff0e\u7b2c 60 \u56de\u65e5\u672c\u80ba\u764c\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012019\uff0e12\uff08\u5927\u962a\uff09<\/li>\n\n\n\n<li>\u5ca1\u5185\u771e\u4e00\u90ce\u3001\u540d\u548c \u5065\u3001\u5c71\u7530\u82f1\u6075\u3001\u93d1\u6728\u5b5d\u4e4b\u3001\u4e2d\u6fa4\u5065\u4ecb\u3001\u6a9c\u6fa4\u4f38\u4e4b\u3001\u77f3\u5ddd\u535a\u4e00\u3001\u6728\u6751\u6b63\u6a39\u3001\u4e2d\u6751\u535a\u5e78\u3001\u91ce\u6751 \u660e\u5e83\u3001\u4f50\u85e4 \u6d69\u662d\uff0e\u8328\u57ce\u80ba\u764c\u7814\u7a76\u4f1a(POSITIVE \u7814\u7a76\u30b0\u30eb\u30fc\u30d7)\uff0eALK \u878d\u5408\u907a\u4f1d\u5b50\u967d\u6027\u80ba\u764c \u306e\u60a3\u8005\u7279\u6027\u30fb\u6cbb\u7642\u3068\u4e88\u5f8c\u306e\u95a2\u9023\uff0e\u7b2c 60 \u56de\u65e5\u672c\u80ba\u764c\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012019\uff0e12\uff08\u5927\u962a\uff09<\/li>\n\n\n\n<li>\u5c0f\u7af9\u7f8e\u7d75\u3001\u4eca\u4e95\u4e45\u96c4\u3001\u5c71\u7530 \u8c4a\u3001\u93d1\u6728\u5b5d\u4e4b\u3001\u6e05\u5d8b\u8b77\u4e4b\u3001\u6749\u5c71\u667a\u82f1\u3001\u4e2d\u6751\u6d0b\u4e00\u3001\u7b20\u4e95 \u5c1a\u3001\u677e\u9688\u6cbb\u4e45\u3001\u85e4\u7530 \u6566\u3001\u6e4a \u6d69\u4e00\uff0e\u8853\u5f8c\u88dc\u52a9\u5316\u5b66\u7642\u6cd5\u3092\u884c\u3063\u305f\u9ad8\u60aa\u6027\u5ea6\u795e\u7d4c\u5185\u5206\u6ccc\u80ba\u764c\u60a3\u8005\u306e\u9577\u671f\u4e88\u5f8c\u306e\u691c\u8a0e\uff0e\u7b2c 60 \u56de\u65e5\u672c\u80ba\u764c\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012019\uff0e12\uff08\u5927\u962a\uff09<\/li>\n\n\n\n<li>\u5c71\u7530 \u8c4a\u3001\u677e\u5009\u3057\u307b\u308a\u3001\u7530\u6751\u667a\u5b8f\u3001\u5409\u5ddd\u5f25\u9808\u5b50\u3001\u5c71\u53e3\u662d\u4e09\u90ce\u3001\u6a4b\u672c\u5e7e\u592a\u3001\u93d1\u6728\u5b5d\u4e4b\uff0e\u5598\u606f\u75c7\u72b6\u306e\u306a \u3044\u80ba\u30a2\u30b9\u30da\u30eb\u30ae\u30eb\u30b9\u75c7\u306e 1 \u4f8b\uff0e\u7b2c 172 \u56de\u547c\u5438\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u95a2\u6771\u652f\u90e8\u4f1a\u3001\u7d19\u4e0a\u958b\u50ac\uff082020.3\uff09<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u5e73\u621030\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Imai H\uff0cMinemura H\uff0cSugiyam T, Yamada Y\uff0cKaira K\uff0cKanazawa K\uff0cKasai T\uff0cKaburagi T\uff0cMinato K \uff0e Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR\u2013TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations.Cancer Chemother Pharmacol. 82(1):119-127, 2018<\/li>\n\n\n\n<li>Niho S\uff0cIkeda N, Michimae H, Suzuki K, Sakai H, Kaburagi T, Yoshiya K, Minato K, Kato T, Okamoto H, Seto T, Hosomi Y, Shimizu K, Saito H, Tsuchida M, Kunitoh H, Tsuboi M, Takeuchi M, Watanabe K. Overall survival results of the feasibility study of adjuvant chemotherapy with Docetaxel Plus Cisplatin followed by long-term single-agent administration of S-1 in Patients with completely resected non-small cell lung cancer: Thoracic Oncology Research Group (TORG)Am J Clin Oncol. 2018 Mar 7. [Epub ahead of print]<\/li>\n\n\n\n<li>Kaburagi T\uff0cKiyoshima M, Nawa T, Ichimura H, Saito T, Hayashihara K, Yamada H, Satoh H, Endo T, Inage Y, Saito K, Inagaki M, Hizawa N, Sato Y, Ishikawa H, Sakai M, Kamiyama K, Kikuchi N, Nakamura H, Furukawa K, Kodama T, Yamashita T, Nomura A, Yoshida S. Acquired EGFR T790M mutation after relapse following EGFR-TKI therapy: a populationbased multiinstitutional study. Anticancer Res. 38(5):3145-3150, 2018.<\/li>\n\n\n\n<li>Miyazaki K\uff0cTamura T, Kaburagi T, Saito K, Inagaki M, Yamashita T, Ichimura H, Nawa T, Endo T, Hayashihara K, Kimura M, Kurishima K, Nakamura H, Furukawa K, Kikuchi N, Satoh H, Hizawa N. Real clinical practice of using afatinib therapy in NSCLC patients with an acquired EGFR T790M mutation. Anticancer Res. 38(9):5409-5415, 2018.<\/li>\n\n\n\n<li>Imai H\uff0cYamada Y, Minemura H, Sugiyama T, Kotake M, Kaira K, Kanazawa K, Nakamura Y, Kasai T, Shibata Y, Kaburagi T, Minato K. Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis. Thorac Cancer. 9(12):1699-2018.<\/li>\n\n\n\n<li>Ohgami M\uff0cKaburagi T, Kurosawa A, Doki K, Shiozawa T, Hizawa N, Homma M. Effects of proton pump inhibitor coadministration on the plasma concentration of erlotinib in patients with non-small cell lung cancer. Ther Drug Monit. 40(6):699-704, 2018.<\/li>\n\n\n\n<li>Imai H\uff0cYamada Y, Sugiyama T, Minemura H, Kaira K, Kanazawa K, Kasai T, Kaburagi T, Minato<br>K. Clinical impact of post-progression survival on overall survival in elderly patients with nonsmall-cell lung cancer harboring sensitive EGFR mutations treated with first-line EGFR tyrosine kinase inhibitors. Chemotherapy. 63(3):181-189, 2018.<\/li>\n\n\n\n<li>Takahashi H\uff0cKiyoshimac M, Kaburagi T, Hoshiai S, Mori K, Koyama K, Iijima,T. Ishiguro, Hosokawa T, Minami M\uff0e Influence of radiologic expertise in detecting lung tumors on chest radiographs. Diagn Interv Imaging. 100(2):95-107, 2019<\/li>\n\n\n\n<li>Ishii S\uff0cIshii Y, Kaburagi T, Nakano T. Usefulness of new flex-rigid pleuroscopy in the diagnosis of malignant pleural mesothelioma. BMJ Case Rep. 12(1), 2019.<\/li>\n\n\n\n<li>Hosomi Y\uff0cTanai C, Yoh K, Goto Y, Sakai H, Kato T, Kaburagi T. Nishio M, Kim YH, Inoue A, Hasegawa Y, Isobe H, Tomizawa Y, Mori Y, Minato K, Yamada K, Ohashi Y, Kunito H. Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression.Expert Opin Pharmacother. 19(10):1049-1056, 2018<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u5927\u5cf6\u592e\u4e4b\u3001\u5c71\u7530\u8c4a\u3001\u7530\u6751\u667a\u5b8f\u3001\u5409\u5ddd\u5f25\u9808\u5b50\u3001\u5c71\u53e3\u662d\u4e09\u90ce\u3001\u6a4b\u672c\u5e7e\u592a\u3001\u5ddd\u7aef\u4fca\u592a\u90ce\u3001\u9234\u6728\u4e45\u53f2\u3001\u6e05\u5d8b\u8b77\u4e4b\u3001\u7389\u6728\u7fa9\u96c4\u3001\u6589\u85e4\u4ec1\u662d\u3001\u98ef\u5d8b\u9054\u751f\u3001\u93d1\u6728\u5b5d\u4e4b. \u82e5\u5e74\u80ba\u817a\u764c\u8853\u5f8c\u6c17\u7ba1\u518d\u767a\u306e\u4e00\u4f8b. \u7b2c 44 \u8328\u57ce\u770c\u80ba\u764c\u7814\u7a76\u4f1a\u30012018.3\uff08\u7b20\u9593\uff09<\/li>\n<\/ol>\n\n\n\n<ol start=\"2\" class=\"wp-block-list\">\n<li>\u7530\u6751\u667a\u5b8f\u3001\u5927\u5cf6\u592e\u4e4b\u3001\u5c71\u7530\u8c4a\u3001\u5409\u5ddd\u5f25\u9808\u5b50\u3001\u5c71\u53e3\u662d\u4e09\u90ce\u3001\u6a4b\u672c\u5e7e\u592a\u3001\u93d1\u6728\u5b5d\u4e4b\u3001\u4f50\u85e4\u6d69\u662d\u3001\u6a9c\u6fa4\u4f38\u4e4b. \u30da\u30e0\u30d6\u30ed\u30ea\u30ba\u30de\u30d6\u6295\u4e0e\u4e2d\u306b\u7532\u72b6\u817a\u6a5f\u80fd\u4f4e\u4e0b\u75c7\u3068\u7d9a\u767a\u6027\u526f\u814e\u4e0d\u5168\u3092\u540c\u6642\u306b\u6765\u3057\u305f\u75c7\u4f8b\u306e\u691c\u8a0e. \u7b2c 58 \u56de\u547c\u5438\u5668\u5b66\u4f1a\u30012018.4\uff08\u5927\u962a\uff09<\/li>\n\n\n\n<li>\u5927\u5cf6\u592e\u4e4b\u3001\u5c71\u7530\u8c4a\u3001\u7530\u6751\u667a\u5b8f\u3001\u5409\u5ddd\u5f25\u9808\u5b50\u3001\u5c71\u53e3\u662d\u4e09\u90ce\u3001\u6a4b\u672c\u5e7e\u592a\u3001\u5ddd\u7aef\u4fca\u592a\u90ce\u3001\u9234\u6728\u4e45\u53f2\u3001\u6e05\u5d8b\u8b77\u4e4b\u3001\u7389\u6728\u7fa9\u96c4\u3001\u6589\u85e4\u4ec1\u662d\u3001\u98ef\u5d8b\u9054\u751f\u3001\u93d1\u6728\u5b5d\u4e4b. \u82e5\u5e74\u80ba\u817a\u764c\u8853\u5f8c\u6c17\u7ba1\u518d\u767a\u306e\u4e00\u4f8b. \u7b2c 58 \u56de\u547c\u5438\u5668\u5b66\u4f1a\u30012018.4\uff08\u5927\u962a\uff09<\/li>\n\n\n\n<li>\u5927\u4e45\u4fdd\u521d\u7f8e\u3001\u5927\u5cf6\u592e\u4e4b\u3001\u5c71\u7530\u8c4a\u3001\u7530\u6751\u667a\u5b8f\u3001\u5409\u5ddd\u5f25\u9808\u5b50\u3001\u5c71\u53e3\u662d\u4e09\u90ce\u3001\u6a4b\u672c\u5e7e\u592a\u3001\u93d1\u6728\u5b5d\u4e4b. \u900f\u6790\u60a3\u8005\u306e\u5c40\u6240\u9ebb\u9154\u4e0b\u80f8\u8154\u93e1\u6240\u898b\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e. \u7b2c 58 \u56de\u547c\u5438\u5668\u5b66\u4f1a\u30012018.4\uff08\u5927\u962a\uff09<\/li>\n\n\n\n<li>\u4eca\u4e95\u4e45\u96c4\u3001\u5cef\u6751\u6d69\u4e4b\u3001\u6749\u5c71\u667a\u82f1\u3001\u5c71\u7530\u8c4a\u3001\u89e3\u826f\u606d\u4e00\u3001\u91d1\u6ca2\u8ce2\u4e5f\u3001\u7b20\u4e95\u5c1a\u3001\u93d1\u6728\u5b5d\u4e4b\u3001\u6e4a\u6d69\u4e00. \u9ad8\u9f62\u8005\u521d\u56de EGFR-TKI \u5f8c\u306e 2 \u6b21\u6cbb\u7642\u3068\u3057\u3066\u306e\u6bba\u7d30\u80de\u6027\u6297\u304c\u3093\u5264\u306e\u691c\u8a0e. \u7b2c 58 \u56de\u547c\u5438\u5668\u5b66\u4f1a\u30012018.4\uff08\u5927\u962a\uff09<\/li>\n\n\n\n<li>\u5c71\u7530\u8c4a\u3001\u93d1\u6728\u5b5d\u4e4b\u3001\u5927\u5cf6\u592e\u4e4b\u3001\u7530\u6751\u667a\u5b8f\u3001\u5409\u5ddd\u5f25\u9808\u5b50\u3001\u5c71\u53e3\u662d\u4e09\u90ce\u3001\u6a4b\u672c\u5e7e\u592a\u3001\u96e8\u5bae\u9686\u592a. \u5c40\u6240\u9ebb\u9154\u4e0b\u80f8\u8154\u93e1\u30d7\u30ed\u30c8\u30bf\u30a4\u30d7 LTF-Y0032 \u306e\u4f7f\u7528\u7d4c\u9a13\u306b\u3064\u3044\u3066. \u7b2c 41 \u56de\u65e5\u672c\u547c\u5438\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u5b66 \u8853\u96c6\u4f1a\u30012018.5\uff08\u6771\u4eac\uff09<\/li>\n\n\n\n<li>\u5c71\u53e3\u662d\u4e09\u90ce\u3001\u93d1\u6728\u5b5d\u4e4b\u3001\u4e95\u4e0a\u771f\u4f50\u5b50\u3001\u5927\u5cf6\u592e\u4e4b\u3001\u5927\u4e45\u4fdd\u521d\u7f8e\u3001\u5cf6\u7530\u68a8\u6c99\u3001\u5c71\u7530\u8c4a\u3001\u7530\u6751\u667a\u5b8f\u3001\u5409\u5ddd\u5f25\u9808\u5b50\u3001\u6a4b\u672c\u5e7e\u592a\u3001\u96e8\u5bae\u9686\u592a. \u81bf\u80f8\u3084\u80ba\u708e\u968f\u4f34\u80f8\u6c34\u75c7\u4f8b\u306b\u5bfe\u3057\u3001\u5c40\u6240\u9ebb\u9154\u4e0b\u80f8\u8154\u93e1\u65bd\u884c\u6642\u306b\u7d44\u7e54\u57f9\u990a\u3092\u884c\u3046\u610f\u7fa9. \u7b2c 41 \u56de\u65e5\u672c\u547c\u5438\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012018.5\uff08\u6771\u4eac\uff09<\/li>\n\n\n\n<li>\u6a4b\u672c\u5e7e\u592a\u3001\u5c71\u53e3\u662d\u4e09\u90ce\u3001\u5bae\u5ddd\u5c1a\u7f8e\u3001\u77f3\u4e95\u548c\u5b50\u3001\u5409\u5ddd\u5f25\u9808\u5b50\u3001\u93d1\u6728\u5b5d\u4e4b. \u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u53ca\u3073\u5b9a\u671f\u691c\u8a3a\u3001\u63a5\u89e6\u8005\u691c\u8a3a\u304b\u3089\u307f\u305f\u80ba\u7d50\u6838\u611f\u67d3\u30ea\u30b9\u30af\u56e0\u5b50\u306e\u691c\u8a0e. \u7b2c 92 \u56de\u65e5\u672c\u611f\u67d3\u75c7\u5b66\u4f1a\u5b66\u8853\u8b1b\u6f14\u4f1a\u30fb\u7b2c66 \u56de\u65e5\u672c\u5316\u5b66\u7642\u6cd5\u5b66\u4f1a\u7dcf\u4f1a\u5408\u540c\u5b66\u4f1a\u5b66\u30012018.5\uff08\u5ca1\u5c71\uff09<\/li>\n\n\n\n<li>\u5409\u5ddd\u5f25\u9808\u5b50\u3001\u6a4b\u672c\u5e7e\u592a\u3001\u78ef\u7530\u9054\u4e5f\u3001\u5927\u5cf6\u592e\u4e4b\u3001\u5c71\u7530\u8c4a\u3001\u7530\u6751\u667a\u5b8f\u3001\u5c71\u53e3\u662d\u4e09\u90ce\u3001\u93d1\u6728\u5b5d\u4e4b. \u5f53\u9662\u306b\u304a\u3051\u308b\u30a4\u30bd\u30cb\u30a2\u30b8\u30c9\u8010\u6027\u7d50\u6838\u75c7\u306e\u767a\u751f\u5730\u57df\u3068\u81e8\u5e8a\u50cf\u306e\u691c\u8a0e. \u7b2c 93 \u56de\u65e5\u672c\u7d50\u6838\u75c5\u7dcf\u4f1a\u30012018.6.\uff08\u5927\u962a\uff09<\/li>\n\n\n\n<li>Imai H\uff0cYutaka Yamada Y\uff0cSugiyama T\uff0cMinemura H\uff0cKaira K\uff0cKanazawa K\uff0cKasai T\uff0cKaburagi T\uff0cMinato K\uff0eValue of post-progression survival in elderly EGFR-mutated nonsmall-cell lung cancer\uff0e\u7b2c 16 \u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a,2018.7\uff08\u795e\u6238\uff09<\/li>\n\n\n\n<li>Yamada Y\uff0cImai H\uff0cSugiyama T\uff0cMinemura H, Kaira K\uff0cKanazawa K\uff0cKasai T\uff0cKaburagi T\uff0cMinato K\uff0eEfficacy and Safety of Cytotoxic Drug Chemotherapy After First-Line EGFRTKI in Elderly Patients with NSCLC Harboring Sensitive EGFR Mutations \uff0e 19th IASLC World Conference on Lung Cancer (WCLC) ,2018.9\uff08\u30ab\u30ca\u30c0\uff09<\/li>\n\n\n\n<li>\u7530\u6751\u667a\u5b8f\u3001\u93d1\u6728\u5b5d\u4e4b\u3001\u6e05\u5d8b\u8b77\u4e4b\u3001\u4f50\u85e4\u6d69\u662d\u3001\u5c71\u4e0b\u9ad8\u660e\u3001\u9f4a\u85e4\u548c\u4eba\u3001\u5869\u6fa4\u4fca\u535a\u3001\u6a9c\u6fa4\u4f38\u4e4b\u3001\u77f3\u5ddd\u535a\u4e00\u3001\u5150\u7389\u5b5d\u79c0\u3001\u6797\u539f\u8ce2\u6cbb\u3001\u9060\u85e4\u5efa\u592b\u3001\u53e4\u5ddd\u6b23\u4e5f\u3001\u795e\u5c71\u5e78\u4e00\u3001\u7a32\u57a3\u96c5\u6625\u3001\u540d\u548c\u5065\u3001\u5e02\u6751\u79c0\u592b\u3001\u4e2d\u6751\u535a\u5e78\u3001\u83ca\u5730\u6559\u5927. \u30a2\u30d5\u30a1\u30cb\u30c1\u30d6\u6cbb\u7642\u5f8c\u306b T790M \u907a\u4f1d\u5b50\u5909\u7570\u3092\u6e2c\u5b9a\u3057\u305f\u75c7\u4f8b\u306e\u5f8c\u6cbb\u7642\u95a2\u3059\u308b\u691c\u8a0e. \u7b2c 59 \u56de\u65e5\u672c\u80ba\u764c\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012018.11.29-12.1\uff08\u6771\u4eac\uff09<\/li>\n\n\n\n<li>\u5bae\u5d0e\u90a6\u5f66\u3001\u4f50\u85e4\u4fe1\u4e5f\u3001\u5150\u7389\u5b5d\u79c0\u3001\u5c3e\u5f62\u670b\u4e4b\u3001\u9f8d\u795e\u8061\u5b50\u3001\u5c71\u4e0b\u5c06\u5e73\u3001\u5927\u5cf6\u592e\u4e4b\u3001\u5c71\u7530\u8c4a\u3001\u7530\u6751\u667a\u5b8f\u3001\u6e05\u5d8b\u8b77\u4e4b\u3001\u9234\u6728\u4e45\u53f2\u3001\u9ad8\u6a4b\u548c\u5f66\u3001\u65b0\u6751\u5353\u4e5f\u3001\u5b88\u8c37\u53cb\u535a\u3001\u5c71\u5ca1\u8ce2\u4fca\u3001\u5c0f\u8cab\u7422\u54c9\u3001\u7a32\u57a3\u96c5\u6625. \u8328\u57ce\u770c\u306b\u304a\u3051\u308b EGFR-TKI \u6295\u4e0e\u5f8c\u306e T790M \u907a\u4f1d\u5b50\u767a\u73fe\u306b\u95a2\u3059\u308b\u591a\u65bd\u8a2d\u5171\u540c\u7814\u7a76 \u691c\u4f53\u5225\u306e\u89e3\u6790.\u7b2c59 \u56de\u65e5\u672c\u80ba\u764c\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012018.11.29-12.1\uff08\u6771\u4eac\uff09<\/li>\n\n\n\n<li>\u4eca\u4e95\u4e45\u96c4\u3001\u5cef\u6751\u6d69\u4e4b\u3001\u6749\u5c71\u667a\u82f1\u3001\u5c71\u7530\u8c4a\u3001\u5c0f\u7af9\u7f8e\u7d75\u3001\u89e3\u826f\u606d\u4e00\u3001\u91d1\u6ca2\u8ce2\u4e5f\u3001\u7b20\u4e95\u5c1a\u3001\u93d1\u6728\u5b5d\u4e4b\u3001\u6e4a\u6d69\u4e00. \u9ad8\u9f62\u8005\u521d\u56de EGFR-TKI \u5f8c\u306e 2 \u6b21\u6cbb\u7642\u3068\u3057\u3066\u306e\u6bba\u7d30\u80de\u6027\u6297\u304c\u3093\u85ac\u306e\u52b9\u679c\u304a\u3088\u3073\u5b89\u5168\u5e02\u306e \u691c\u8a0e.\u7b2c 59 \u56de\u65e5\u672c\u80ba\u764c\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012018.11.29-12.1\uff08\u6771\u4eac\uff09<\/li>\n\n\n\n<li>\u5c71\u7530\u8c4a\u3001\u4eca\u4e95\u4e45\u96c4\u3001\u5c0f\u7af9\u7f8e\u7d75\u3001\u5cef\u6751\u6d69\u4e4b\u3001\u91d1\u6ca2\u8ce2\u4e5f\u3001\u6749\u5c71\u667a\u82f1\u3001\u4e2d\u6751\u6d0b\u4e00\u3001\u89e3\u826f\u606d\u4e00\u3001\u93d1\u6728\u5b5d\u4e4b\u3001\u67f4\u7530\u967d\u5149\u3001\u7b20\u4e95\u5c1a\u3001\u6e4a\u6d69\u4e00. \u9ad8\u9f62\u8005\u518d\u767a\u5c0f\u7d30\u80de\u80ba\u764c\u306b\u5bfe\u3059\u308b\u30c8\u30dd\u30c6\u30ab\u30f3\u5358\u72ec\u7642\u6cd5\u306e\u5f8c\u308d\u5411\u304d\u7814\u7a76.\u7b2c 59 \u56de\u65e5\u672c\u80ba\u764c\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012018.11.29-12.1\uff08\u6771\u4eac\uff09<\/li>\n\n\n\n<li>\u5cef\u6751\u6d69\u4e4b\u3001\u68ee\u8c37\u6d69\u53f2\u3001\u4eca\u4e95\u4e45\u96c4\u3001\u6749\u5c71\u667a\u82f1\u3001\u5c71\u7530\u8c4a\u3001\u6a0b\u53e3\u5149\u5fb3\u3001\u89e3\u826f\u606d\u4e00\u3001\u5c3e\u5d0e\u6709\u7d00\u3001\u91d1\u6ca2\u8ce2\u4e5f\u3001\u6a2a\u5185\u6d69\u3001\u7b20\u4e95\u5c1a\u3001\u93d1\u6728\u5b5d\u4e4b\u3001\u9234\u6728\u5f18\u884c\u3001\u6e4a\u6d69\u4e00\u3001\u67f4\u7530\u967d\u5149. CT \u753b\u50cf\u6240\u898b\u3068\u30cb\u30dc\u30eb\u30de\u30d6\u306e\u6cbb\u7642\u52b9\u679c\u306b\u95a2\u3059\u308b\u691c\u8a0e\uff08GIFT-04\/Fight-03).\u7b2c 59 \u56de\u65e5\u672c\u80ba\u764c\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012018.11.29-12.1\uff08\u6771\u4eac\uff09<\/li>\n\n\n\n<li>\u4e7e\u5e74\u79c0\u3001\u5c71\u7530\u8c4a\u3001\u7530\u6751\u667a\u5b8f\u3001\u5409\u5ddd\u5f25\u9808\u5b50\u3001\u5c71\u53e3\u662d\u4e09\u90ce\u3001\u6a4b\u672c\u5e7e\u592a\u3001\u93d1\u6728\u5b5d\u4e4b\u3001\u98ef\u5d8b\u9054\u751f. \u30da\u30e1\u30c8\u30ec\u30ad\u30bb\u30c9\u5358\u5264\u6cbb\u7642\u3067\u9577\u671f\u7e2e\u5c0f\u7dad\u6301\u3057\u3066\u3044\u308b ALK \u907a\u4f1d\u5b50\u8ee2\u5ea7\u967d\u6027\u80ba\u817a\u764c\u306e 1 \u4f8b.\u7b2c 46 \u8328\u57ce\u770c\u80ba\u764c \u7814\u7a76\u4f1a\u30012019.3\uff08\u6c34\u6238\uff09<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u5e73\u621029\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u8457\u66f8\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Tamura T, Takagi Y, Okubo H, Yamaguchi S, Kikkawa Y, Hashimoto I, Kaburagi T, Miura M,Satoh H, Hizawa N. Plasma concentration of osimertinib in a non-small cell lung cancer patient with chronic renal failure undergoing hemodialysis\uff0cLung Cancer. 112:225-226\uff0c2017.<\/li>\n\n\n\n<li>Imai H, Sugiyama T, Tamura T, Minemura H, Kaira K, Kanazawa K, Yokouchi H, Kasai T, Kaburagi T, Minato K. A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients\uff0cCancer Chemother Pharmacol. 80(3):615-622\uff0c2017.<\/li>\n\n\n\n<li>GotoY, Tanai C, Yoh K, Hosomi Y, Sakai H, Kato T, Kaburagi T, Nishio M, Kim YH, Inoue A, Hasegawa Y, Isobe H, Tomizawa Y, Mori Y, Minato K, Yamada K, Ohashi Y, Kunitoh H. DOI: Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study\uff0cESMO Open. 2(4):\uff0c2017.<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u7530\u6751\u667a\u5b8f\uff0c\u9ad9\u6728\u96c4\u57fa\uff0c\u5927\u4e45\u4fdd\u521d\u7f8e\uff0c\u5409\u5ddd\u5f25\u9808\u5b50\uff0c\u5c71\u53e3\u662d\u4e09\u90ce\uff0c\u6a4b\u672c\u5e7e\u592a\uff0c\u93d1\u6728\u5b5d\u4e4b\uff0c\u6162\u6027\u814e\u4e0d\u5168\u5408\u4f75\u80ba\u817a\u764c \u306b\u5bfe\u3059\u308b\u30aa\u30b7\u30e1\u30eb\u30c1\u30cb\u30d6\u6295\u4e0e\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e\uff0c\u7b2c 57 \u56de\u65e5\u672c\u547c\u5438\u5668\u5b66\u4f1a\u5b66\u8853\u8b1b\u6f14\u4f1a\uff0c2017\uff0e4\uff08\u6771\u4eac\uff09<\/li>\n<\/ol>\n\n\n\n<ol start=\"2\" class=\"wp-block-list\">\n<li>\u5927\u4e45\u4fdd\u521d\u7f8e\uff0c\u9ad9\u6728\u96c4\u57fa\uff0c\u7530\u6751\u667a\u5b8f\uff0c\u5409\u5ddd\u5f25\u9808\u5b50\uff0c\u5c71\u53e3\u662d\u4e09\u90ce\uff0c\u6a4b\u672c\u5e7e\u592a\uff0c\u93d1\u6728\u5b5d\u4e4b\uff0c\u7b2c 57 \u56de\u65e5\u672c\u547c\u5438\u5668\u5b66 \u4f1a\u5b66\u8853\u8b1b\u6f14\u4f1a\uff0c2017.4\uff08\u6771\u4eac\uff09<\/li>\n\n\n\n<li>\u5c71\u53e3\u662d\u4e09\u90ce\uff0c\u93d1\u6728\u5b5d\u4e4b\uff0c\u5185\u6d77\u5553\u5b50\uff0c\u9ad9\u6728\u96c4\u57fa\uff0c\u5927\u4e45\u4fdd\u521d\u7f8e\uff0c\u5cf6\u7530\u68a8\u6c99\uff0c\u5c71\u7530\u8c4a\uff0c\u7530\u6751\u667a\u5b8f\uff0c\u5409\u5ddd\u5f25\u9808\u5b50\uff0c\u6a4b \u672c\u5e7e\u592a\uff0c\u96e8\u5bae\u9686\u592a\uff0c\u7b2c 40 \u56de\u547c\u5438\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u5b66\u8853\u8b1b\u6f14\u4f1a\uff0c2017. 6\uff08\u9577\u5d0e\uff09<\/li>\n\n\n\n<li>\u5c71\u7530\u8c4a\uff0c\u5897\u7530\u7f8e\u667a\u5b50\u30fb\u963f\u91ce\u54f2\u58eb\u30fb\u83ca\u6c60\u6559\u5927\u30fb\u77f3\u4e95\u5e78\u96c4\uff08\u72ec\u7acb\u884c\u653f\u6cd5\u4eba\u56fd\u7acb\u75c5\u9662\u6a5f\u69cb\u971e\u30f6\u6d66\u533b\u7642\u30bb\u30f3\u30bf\u30fc\uff09\u80f8 \u90e8\u7570\u5e38\u9670\u5f71\u306e\u7cbe\u67fb\u76ee\u7684\u3067\u65bd\u884c\u3057\u305f\u6c17\u7ba1\u652f\u93e1\u306b\u3066\u8a3a\u65ad\u78ba\u5b9a\u3057\u305f\u6c17\u7ba1\u652f\u7d50\u6838\u306e 1 \u4f8b\uff0c\u7b2c 40 \u56de\u65e5\u672c\u547c\u5438\u5668\u5185\u8996\u93e1 \u5b66\u4f1a\u5b66\u8853\u8b1b\u6f14\u4f1a\uff0c2017. 6\uff08\u9577\u5d0e\uff09<\/li>\n\n\n\n<li>\u7530\u6751\u667a\u5b8f\uff0c\u4eca\u4e95\u4e45\u96c4, \u6749\u5c71\u667a\u82f1, \u5cef\u6751\u6d69\u4e4b, \u89e3\u826f\u606d\u4e00, \u91d1\u6ca2\u8ce2\u4e5f, \u6a2a\u5185\u6d69, \u7b20\u4e95\u5c1a, \u93d1\u6728\u5b5d\u4e4b, \u6e4a\u6d69\u4e00\uff0cA retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients\uff0c\u7b2c 15 \u56de\u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2017. 7\uff08\u795e\u6238\uff09<\/li>\n\n\n\n<li>\u5927\u5cf6\u592e\u4e4b\uff0c\u5409\u5ddd\u5f25\u9808\u5b50,\u5150\u5c71\u5065,\u5c71\u7530\u8c4a\u300d,\u7530\u6751\u667a\u5b8f,\u5c71\u53e3\u662d\u4e09\u90ce,\u6a4b\u672c\u5e7e\u592a,\u93d1\u6728\u5b5d\u4e4b\uff0c\u7247\u5074\u633f\u7ba1\u4e0b\u306b\u6c17\u7ba1\u652f\u52d5\u8108 \u585e\u6813\u8853\u3092\u53cd\u5fa9\u3057\u305f\u80ba\u30a2\u30b9\u30da\u30eb\u30ae\u30eb\u30b9\u75c7\u306e\u5927\u91cf\u5580\u8840\u306e\u4e00\u4f8b\uff0c\u7b2c 172 \u56de\u65e5\u672c\u7d50\u6838\u75c5\u5b66\u4f1a\u95a2\u6771\u652f\u90e8\u4f1a\u30fb\u7b2c 226 \u56de \u65e5\u672c\u547c\u5438\u5668\u5b66\u4f1a\u95a2\u6771\u5730\u65b9\u4f1a\u5408\u540c\u5b66\u4f1a\uff0c2017. 9\uff08\u3064\u304f\u3070\uff09<\/li>\n\n\n\n<li>\u7530\u6751\u667a\u5b8f\uff0c\u5927\u5cf6\u592e\u4e4b\uff0c\u5c71\u7530\u8c4a\uff0c\u5409\u5ddd\u5f25\u9808\u5b50\uff0c\u5c71\u53e3\u662d\u4e09\u90ce\uff0c\u6a4b\u672c\u5e7e\u592a\uff0c\u93d1\u6728\u5b5d\u4e4b, \u5f53\u9662\u306b\u304a\u3051\u308b EGFRT790M \u8840\u6f3f\u691c\u67fb\u306e\u691c\u8a0e\uff0c\u7b2c 58 \u56de\u65e5\u672c\u80ba\u764c\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2017. 10\uff08\u6a2a\u6d5c\uff09<\/li>\n\n\n\n<li>\u5927\u5cf6\u592e\u4e4b\uff0c\u6817\u5cf6\u6d69,\u5d8b\u7530\u8cb4\u6587,\u5c0f\u539f\u4e00\u8a18,\u85e4\u7530\u7d14\u4e00,\u91d1\u672c\u5e78\u53f8,\u98ef\u5cf6\u5f18\u6643,\u4e95\u7530\u6566\u5b50,\u6cc9\u73b2\u5b50,\u82e5\u83dc\u6075,\u5c0f\u897f \u6843\u5b50,\u9ce9\u8c9d\u53cb\u7f8e,\u77f3\u5ddd\u535a\u4e00,\u4f50\u85e4\u6d69\u662d\uff0c\u2163\u671f\u975e\u5c0f\u7d30\u80de\u764c\u306b\u304a\u3051\u308b Body Mass Index \u304a\u3088\u3073modified Glasgow Prognostic Score \u306e\u81e8\u5e8a\u7684\u691c\u8a0e\uff0c2017. 10\uff08\u6a2a\u6d5c\uff09<\/li>\n\n\n\n<li>Harada D, Yamada K, Tanaka H, Kubota K, Kishi K, Shimokawa T, Saito H, Takiguchi Y, Hosomi Y, Kato T, Nogami N, Masuda N, Kasai T, Minato K, Kaburagi T, Naoki K, Nakamura Y,Yamanaka T, Okamoto H. Randomized Phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer: TORG1018\uff0c\u7b2c 58 \u56de\u65e5\u672c\u80ba\u764c \u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2017. 10\uff08\u6a2a\u6d5c\uff09<\/li>\n\n\n\n<li>\u5c0f\u897f\u91cc\u6c99\u3001\u5927\u4e45\u4fdd\u521d\u7f8e\u3001\u9ad8\u6728\u96c4\u57fa\u3001\u7530\u6751\u667a\u5b8f\u3001\u5409\u5ddd\u5f25\u9808\u5b50\u3001\u5c71\u53e3\u662d\u4e09\u90ce\u3001\u6a4b\u672c\u5e7e\u592a\u3001\u93d1\u6728\u5b5d\u4e4b. \u764c\u6027\u80f8\u819c\u708e \u3067\u767a\u75c7\u3057\u5256\u691c\u3067\u8a3a\u65ad\u306b\u81f3\u3063\u305f\u539f\u767a\u6027\u5927\u8178\u764c\u591a\u81d3\u5668\u8ee2\u79fb\u306e\u4e00\u4f8b\uff0c\u65e5\u672c\u5185\u79d1\u5b66\u4f1a \u7b2c636 \u56de\u95a2\u6771\u5730\u65b9\u4f1a\uff0c2017. 10 \uff08\u6771\u4eac\uff09<\/li>\n\n\n\n<li>\u5c71\u53e3\u662d\u4e09\u90ce\uff0c\u93d1\u6728\u5b5d\u4e4b\uff0c\u4e95\u4e0a\u771f\u4f50\u5b50\uff0c\u5927\u5cf6\u592e\u4e4b\uff0c\u5c71\u7530\u8c4a\uff0c\u7530\u6751\u667a\u5b8f\uff0c\u5409\u5ddd\u5f25\u9808\u5b50\uff0c\u6a4b\u672c\u5e7e\u592a\uff0c\u5f53\u9662\u3067\u306e\u30cb\u30dc \u30eb\u30de\u30d6\u4f7f\u7528\u75c7\u4f8b\u306b\u5bfe\u3059\u308b\u5f8c\u308d\u5411\u304d\u89e3\u6790\uff0c\u7b2c 43 \u8328\u57ce\u80ba\u764c\u7814\u7a76\u4f1a\uff0c2017. 11\uff08\u571f\u6d66\uff09<\/li>\n\n\n\n<li>\u5927\u5cf6\u592e\u4e4b\uff0c\u5c71\u7530\u8c4a,\u7530\u6751\u667a\u5b8f,\u5409\u5ddd\u5f25\u9808\u5b50,\u5c71\u53e3\u662d\u4e09\u90ce,\u6a4b\u672c\u5e7e\u592a,\u5ddd\u7aef\u4fca\u592a\u90ce,\u9234\u6728\u4e45\u53f2,\u6e05\u5d8b\u8b77\u4e4b,\u7389\u6728\u7fa9\u96c4,\u6589\u85e4 \u4ec1\u662d,\u98ef\u5d8b\u9054\u751f,\u93d1\u6728\u5b5d\u4e4b\uff0c\u82e5\u5e74\u80ba\u817a\u764c\u8853\u5f8c\u6c17\u7ba1\u518d\u767a\u306e\u4e00\u4f8b\uff0c\u7b2c 43 \u8328\u57ce\u80ba\u764c\u7814\u7a76\u4f1a\uff0c2017.11\uff08\u571f\u6d66\uff09<\/li>\n\n\n\n<li>\u5c71\u7530\u8c4a\uff0c\u5927\u5cf6\u592e\u4e4b\uff0c\u7530\u6751\u667a\u5b8f\uff0c\u5409\u5ddd\u5f25\u9808\u5b50\uff0c\u5c71\u53e3\u662d\u4e09\u90ce\uff0c\u6a4b\u672c\u5e7e\u592a\uff0c\u93d1\u6728\u5b5d\u4e4b\uff0c\u5c40\u6240\u9ebb\u9154\u4e0b\u80f8\u8154\u93e1\u3067\u8a3a\u65ad\u3057 \u305f\u7d50\u6838\u6027\u80f8\u8179\u819c\u708e\u306e 1 \u4f8b\uff0c\u7b2c 163 \u56de\u547c\u5438\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u95a2\u6771\u652f\u90e8\u4f1a\uff0c2017. 12\uff08\u6771\u4eac\uff09<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\">\u5e73\u621028\u5e74\u5ea6<\/h3>\n\n\n\n<p>\u3010\u8457\u66f8\u30fb\u7dcf\u8aac\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u93d1\u6728\u5b5d\u4e4b \uff0e\u65e5\u672c\u80ba\u764c\u5b66\u4f1a\u7de8\u6c17\u7ba1\u652f\u93e1\u8a3a\u65ad \uff0d \u6b63\u5e38\u6c17\u7ba1\u652f\u93e1\u6240\u898b \u300c \u81e8\u5e8a \u30fb \u75c5\u7406\u80ba\u764c\u53d6\u6271\u3044\u898f\u7d04\u7b2c8\u7248 \u300d .\u91d1 \u539f \u51fa\u7248 \u3001 p p1 4 9 -165\u3001 2 0 1 6<\/li>\n\n\n\n<li>\u5c71\u7530\u8c4a \u3001 \u93d1\u6728\u5b5d\u4e4b \u3001 \u9060\u85e4\u5065\u592b \u3001 \u77f3\u4e95\u5e78\u96c4 \u3001 \u5927\u77f3\u4fee\u53f8 \u3001 \u658e\u85e4\u6b66\u6587 .\u7b2c\u4e00\u7dda\u547c\u5438\u5668\u79d1\u533b\u304c\u56f0\u3063\u305f\u75c7\u4f8b\u304b\u3089 \u5b66\u3093\u3060\u6559\u8a13 . \u514b\u8aa0\u5802\u51fa \u3001 pp1 6 1 -164\u3001 2 0 1 7<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u5c71\u53e3\u662d\u4e09\u90ce \u3001 \u5185\u6d77\u5553\u5b50 , \u963f\u90e8\u6b63\u6d0b , \u5927\u4e45\u4fdd\u521d\u7f8e \uff0c \u6298\u8302\u572d\u4ecb , \u5c71\u7530\u8c4a , \u6a4b\u672c\u5e7e\u592a , \u93d1\u6728\u5b5d\u4e4b \uff0e\u764c\u6027\u80f8\u6c34\u306b\u5bfe\u3059 \u308b\u30bf\u30eb\u30af\u80f8\u819c\u8154\u5185\u6ce8\u5165\u7528\u61f8\u6fc1\u5264 \uff08 \u5546 \u54c1\u540d \uff1a \u30e6 \u30cb \u30bf \u30eb \u30af \uff09\u3092\u7528\u3044\u305f\u5c40\u6240\u9ebb\u9154\u4e0b\u80f8\u8154\u93e1\u306b\u3088\u308b\u80f8\u819c\u7652\u7740\u8853\u306e \u691c\u8a0e\u7b2c56\u56de\u65e5\u672c\u547c\u5438\u5668\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a \u3001 2016 .4\uff08\u4eac\u90fd\uff09<\/li>\n\n\n\n<li>\u5185\u6d77\u5553\u5b50\u3001\u93d1\u6728\u5b5d\u4e4b\u3001\u963f\u90e8\u6b63\u6d0b\u3001\u5927\u4e45\u4fdd\u521d\u7f8e\u3001\u5c71\u7530\u8c4a\u3001\u5c71\u53e3\u662d\u4e09\u90ce\u3001\u6a4b\u672c\u5e7e\u592a\u3001\u96e8\u5bae\u9686\u592a .\u5f53\u9662\u306e\u5c40\u6240\u9ebb \u9154\u4e0b\u80f8\u8154\u93e1\u691c\u67fb\u5c0e\u5165\u5f8c\u306e\u6cbb\u7642\u306e\u5909\u9077\u306b\u3064\u3044\u3066.\u7b2c56\u56de\u65e5\u672c\u547c\u5438\u5668\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a \u30012016 .4\uff08\u4eac\u90fd\uff09<\/li>\n\n\n\n<li>\u7e54\u7b20\u88d5\u884c\u3001\u5927\u4e45\u4fdd\u521d\u7f8e\u3001\u9ad9\u6728\u96c4\u57fa\u3001\u7530\u6751\u667a\u5b8f\u3001\u5409\u5ddd\u5f25\u9808\u5b50 \u3001\u5c71\u53e3\u662d\u4e09\u90ce \u3001\u6a4b\u672c\u5e7e\u592a \u3001\u5c0f\u570b\u82f1\u4e00 \u3001\u93d1\u6728\u5b5d \u4e4b \uff0e\u30bf\u30af\u30ed\u30ea\u30e0\u30b9\u3068\u591a\u5264\u4f75\u7528\u6297\u764c\u5264\u6cbb\u7642\u306b\u3088\u308a\u75c7 \u72b6 \u6539 \u5584 \u3092 \u5f97 \u305f \u91cd \u75c7 \u7b4b \u7121 \u529b \u75c7 \u5408 \u4f75 \u80f8 \u817a \u816b \u306e 1 \u4f8b \uff0e \u7b2c 6 2 6 \u56de \u65e5 \u672c \u5185 \u79d1 \u5b66\u4f1a \u95a2 \u6771 \u5730 \u65b9 \u4f1a \u3001 2 0 16 .9\uff08\u6771\u4eac\uff09<\/li>\n\n\n\n<li>\u93d1\u6728\u5b5d\u4e4b \u3001\u9ad8\u6728\u96c4\u57fa \u3001\u5927\u4e45\u4fdd\u521d\u7f8e \u3001\u5c71\u7530\u8c4a\u3001\u7530\u6751\u667a\u5b8f\u3001\u5409\u5ddd\u5f25\u9808\u5b50\u3001\u5c71\u53e3\u662d\u4e09\u90ce\u3001\u5185\ufa45\u5553\u5b50\u3001\u6a4b\u672c\u5e7e\u592a\u3001  \u96e8\u5bae\u9686\u592a \uff0e\u5c40\u6240\u9ebb\u9154\u4e0b\u80f8\u8154\u93e1\u306e\u57fa\u672c \uff0e\u7b2c39\u56de\u547c\u5438\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u6559\u80b2\u8b1b\u6f14 \u30012016.6\uff08 \u540d\u53e4\u5c4b \uff09<\/li>\n\n\n\n<li>\u5927\u4e45\u4fdd\u521d\u7f8e\u3001\u93d1\u6728\u5b5d\u4e4b\u3001\u9ad8\u6728\u96c4\u57fa\u3001\u5185\u6d77\u5553\u5b50\u3001\u5c71\u53e3\u662d\u4e09\u90ce\u3001\u6a4b\u672c\u5e7e\u592a\u3001\u5317\u539f\u7f8e\u7531\u7d00\u3001\u9234\u6728\u4e45\u53f2\u3001\u6e05\u5d8b\u8b77\u4e4b\u3001 \u96e8\u5bae\u9686\u592a \uff0e \u5c40\u6240\u9ebb\u9154\u4e0b\u80f8\u8154\u93e1\u306b\u304a\u3051\u308b\u4e73\u817a\u539f\u767a\u306e\u764c\u6027\u80f8\u819c\u708e\u306e\u5185\u8996\u93e1\u6240\u898b \uff0e\u7b2c39\u56de\u547c\u5438\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u5b66\u8853 \u96c6\u4f1a \u30012016 .6\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n\n\n\n<li>\u7530\u6751\u667a\u5b8f \u3001\u9ad9\u6728\u96c4\u57fa \u3001\u5927\u4e45\u4fdd\u521d\u7f8e \u3001\u5409\u5ddd\u5f25\u9808\u5b50 \u3001\u5c71\u53e3\u662d\u4e09\u90ce \u3001\u6a4b\u672c\u5e7e\u592a \u3001\u93d1\u6728\u5b5d\u4e4b \uff0e \u7b2c\u4e09\u4e16\u4ee3 EGFR-<br>TKI\u304c\u594f\u529f\u3057\u305f\u6162\u6027\u814e\u4e0d\u5168\u5408\u4f75\u80ba\u817a\u764c\u306e\uff11\u4f8b \uff0e\u7b2c41 \u56de \u8328\u57ce\u80ba\u764c\u7814\u7a76\u4f1a \u30012016 .10\uff08 \u8328\u57ce \uff09<\/li>\n\n\n\n<li>Niho S\uff0cIkeda N\uff0cMichimae H\uff0cSuzuki K\uff0cSakai H\uff0cKaburagi T\uff0cYoshiya K\uff0cMinato K\uff0cKatoT\uff0c Okamo to H\uff0cSeto T\uff0cHosomi Y\uff0cShimizuK\uff0cSaito H\uff0cTsuchida M\uff0cKunitoh H\uff0cTsuboi M, Takeuchi M\uff0cWatana be K\uff0eTORG0809\uff0eFinal overall survival results of the feas ibility study of adjuvant chemotherapy with <br>doc etaxel plus cisplatin followed by maintenance chemotherapy of S -1 in completely resected non &#8211; small cell lung cancer\uff1a Thoracic Oncology Research Group(TORG) 0809\uff0eESMO2016\uff0c2016 .10<br>\uff08 Copenhagen ,Denmark\uff09<\/li>\n\n\n\n<li>\u5927\u4e45\u4fdd\u521d\u7f8e \u3001\u93d1\u6728\u5b5d\u4e4b \u3001\u9ad9\u6728\u96c4\u57fa \u3001\u7530\u6751\u667a\u5b8f \u3001\u5409\u5ddd\u5f25\u9808\u5b50 \u3001\u5c71\u53e3\u662d\u4e09\u90ce \u3001\u6a4b\u672c\u5e7e\u592a \u3001\u9234\u6728\u4e45\u53f2 \u3001\u6e05\u5d8b\u8b77 \u4e4b \u3001\u96e8\u5bae\u9686\u592a \uff0e\u5f53\u9662\u306b\u304a\u3051\u308b\u80ba\u764c\u306b\u8840\u6813\u585e\u6813\u75c7\u3092\u5408\u4f75\u3057\u305f\u75c7\u4f8b\u306e\u691c \u8a0e \uff0e\u7b2c57\u56de\u65e5\u672c\u80ba\u764c\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a \u3001 2016\uff0e1 2\uff08 \u798f\u5ca1 \uff09<\/li>\n\n\n\n<li>\u9ad9\u6728\u96c4\u57fa \u3001\u93d1\u6728\u5b5d\u4e4b \u3001\u5927\u4e45\u4fdd\u521d\u7f8e \u3001\u7530\u6751\u667a\u5b8f \u3001\u5409\u5ddd\u5f25\u9808\u5b50 \u3001\u5c71\u53e3\u662d\u4e09\u90ce \u3001\u6a4b\u672c\u5e7e\u592a \u3001\u9234\u6728\u4e45\u53f2 \u3001\u6e05\u5d8b\u8b77 \u4e4b \u3001\u658e\u85e4\u4ec1\u662d \u3001\u98ef\u5d8b\u9054\u751f \u3001\u96e8\u5bae\u9686\u592a \uff0e\u5f53\u9662\u306b\u304a\u3051\u308b\u80ba\u591a\u5f62\u764c\u5207\u9664\u4f8b\u306e\u81e8\u5e8a\u7684\u691c\u8a0e \uff0e\u7b2c57\u56de\u65e5\u672c\u80ba\u764c\u5b66\u4f1a\u5b66 \u8853\u96c6\u4f1a \u30012016 .12\uff08 \u798f\u5ca1 \uff09<\/li>\n\n\n\n<li>\u9ad8\u8c37\u4e45\u53f2 \u3001\u5c71\u7530\u4e00\u5f66 \u3001\u7530\u4e2d\u6d0b\u53f2 \u3001\u4e45\u4fdd\u7530\u99a8 \u3001\u5cb8\u4e00\u99ac \u3001\u4e0b\u5ddd\u6052 \u751f \u3001\u5ca1\u672c\u6d69\u660e \u3001\u658e\u85e4\u6625\u6d0b \u3001\u6edd\u53e3\u88d5 \u4e00 \u3001\u7d30 \u898b\u5e78\u751f \u3001\u52a0\u85e4\u6643\u53f2 \u3001\u91ce\u4e0a\u5c1a\u4e4b \u3001\u76ca\u7530\u5178\u5e78 \u3001\u7b20\u4e95\u5c1a \u3001\u6e4a\u6d69\u4e00 \u3001\u93d1\u6728\u5b5d\u4e4b \u3001\u6962\u6728\u514b\u5f66 \u3001\u5c71\u4e2d\u7af9\u6625 \u3001\u6e21\u908a\u53e4\u5fd7 \u90ce \uff0e\u6839\u6cbb\u7167\u5c04\u53ef\u80fd\u2162\u671f N S CL C \u306b\u5bfe\u3059\u308b CD D P \uff0b T S- 1 \uff0b T RT \u4f75 \u7528 \u7642 \u6cd5 \u3068 CD D P \uff0bD T X \uff0b T RT \u4f75\u7528\u7642\u6cd5\u306e\u30e9\u30f3\u30c0\u30e0\u5316\u7b2c\u2161\u76f8\u8a66\u9a13 \uff0e\u7b2c57\u56de\u65e5\u672c\u80ba\u764c\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a \uff0e 2016 .12\uff08\u798f\u5ca1\uff09<\/li>\n\n\n\n<li>\u9ad9\u6728\u96c4\u57fa \u3001\u5c71\u53e3\u662d\u4e09\u90ce \u3001\u5927\u4e45\u4fdd\u521d\u7f8e \u3001\u7530\u6751\u667a\u5b8f \u3001\u5409\u5ddd\u5f25\u9808\u5b50 \u3001\u6a4b\u672c\u5e7e\u592a \u3001\u93d1\u6728\u5b5d\u4e4b \uff0e\u764c\u6027\u80f8\u819c\u708e\u3092\u5bfe\u8c61 \u3068\u3057\u305f\u30bf\u30eb\u30af\u3092\u7528\u3044\u305f\u80f8\u819c\u7652\u7740\u8853\u306e\u691c\u8a0e \uff0e\u7b2c26\u56de\u8328\u57ce\u304c\u3093\u5b66\u4f1a \u30012017 .2\uff08\u6c34\u6238\uff09<\/li>\n\n\n\n<li> \u91ce\u53e3\u7fd4\u592a \u3001\u9ad8\u6728\u96c4\u57fa \u3001\u5927\u4e45\u4fdd\u521d\u7f8e \u3001\u7530\u6751\u667a\u5b8f \u3001\u5409\u5ddd\u5f25\u9808\u5b50 \u3001\u5c71\u53e3\u662d\u4e09\u90ce \u3001\u6a4b\u672c\u5e7e\u592a \u3001\u93d1\u6728\u5b5d\u4e4b \uff0e\u9593\u8cea\u6027 \u80ba\u708e\u6cbb\u7642\u4e2d\u306b\u8840\u6813\u5f62\u6210\u304c\u7d4c\u904e\u306b\u5f71\u97ff\u3092\u53ca\u307c\u3057\u305f\u3068\u8003\u3048\u3089\u308c\u308b\u4e00\u4f8b \uff0e\u7b2c209\u56de\u8328\u57ce\u770c\u5185\u79d1\u5b66\u4f1a \u30012017.3\uff08\u6c34\u6238\uff09<\/li>\n\n\n\n<li>\u9ad8\u6728\u96c4\u57fa \u3001\u5927\u4e45\u4fdd\u521d\u7f8e \u3001\u7530\u6751\u667a\u5b8f \u3001\u5409\u5ddd\u5f25\u9808\u5b50 \u3001\u5c71\u53e3\u662d\u4e09\u90ce \u3001\u6a4b\u672c\u5e7e\u592a \u3001\u9234\u6728\u4e45\u53f2 \u3001\u6e05\u5d8b\u8b77\u4e4b \u3001\u96e8\u5bae\u9686 \u592a \uff0e\u30c1\u30e5\u30a2\u30d6\u30eb\u9320\u3092\u8aa4\u56a5\u3057\u6c17\u7ba1\u652f\u93e1\u3067\u9664\u53bb\u3057\u305f1\u4f8b\uff0e\u7b2c 160 \u56de\u65e5\u672c\u547c\u5438\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u95a2\u6771\u652f\u90e8\u4f1a \u30012017 .\uff08\u6771\u4eac\uff09<\/li>\n\n\n\n<li>\u93d1\u6728\u5b5d\u4e4b \uff0e\u521d\u5b66\u8005\u306e\u305f\u3081\u306e\u7d50\u6838\u5bfa\u5b50\u5c4b\u6559\u5ba4\u300c \u7d50\u6838\u6027\u80f8\u819c\u8a3a\u65ad \uff1a \u5c40\u6240\u9ebb\u9154\u4e0b\u80f8\u8154\u93e1\u306e\u5f79\u5272 \u300d \uff0e\u7b2c92\u56de\u65e5\u672c\u7d50 \u6838\u75c5\u5b66\u4f1a \u30012017 .3\uff08\u6771\u4eac\uff09<\/li>\n<\/ol>\n\n\n\n<p>\u3010\u8b1b\u6f14\u3011<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\u7530\u6751\u667a\u5b8f \uff0e\u5f53\u9662\u3067\u306e\u80ba\u764c\u6cbb\u7642\u306e\u5b9f\u969b\u80ba\u764c\u8a3a\u7642\u306b\u304a\u3051\u308b\u30c1\u30fc\u30e0\u533b\u7642\u9023\u643a\u8b1b\u6f14\u4f1a \uff0e\u6c34\u6238\u5354\u540c\u75c5\u9662 \u30012016 .11\uff08\u6c34\u6238\uff09<\/li>\n\n\n\n<li>\u93d1\u6728\u5b5d\u4e4b \uff0e\u7d50\u6838\u6027\u80f8\u819c\u708e\u306e\u8a3a\u65ad\u6c34\u6238\u30c1\u30a7\u30b9\u30c8\u30ab\u30f3\u30d5\u30a1\u30e9\u30f3\u30b9 \uff0e\u6c34\u6238\u533b\u5e2b\u4f1a\u9928 \u30012017 .3<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>\u5e73\u621028\u5e74\u5ea6\uff5e\u4ee4\u548c6\u5e74\u5ea6 \u4ee4\u548c6\u5e74\u5ea6 \u3010\u8457\u66f8\u3011 \u3010\u5b66\u4f1a\u767a\u8868\u3011 \u4ee4\u548c5\u5e74\u5ea6 \u3010\u8457\u66f8\u3011 \u4ee4\u548c4\u5e74\u5ea6 \u3010\u8457\u66f8\u3011 \u3010\u5b66\u4f1a\u767a\u8868\u3011 \u4ee4\u548c3\u5e74\u5ea6 \u3010\u8457\u66f8\u3011 \u3010\u5b66\u4f1a\u767a\u8868\u3011 \u4ee4\u548c\uff12\u5e74\u5ea6 \u3010\u8457\u66f8\u3011 \u3010\u5b66\u4f1a\u767a\u8868\u3011 \u4ee4\u548c\u5143\u5e74\u5ea6 \u3010\u8457\u66f8\u3011 \u3010\u5b66\u4f1a [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":736,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"vk-ltc-link":"","vk-ltc-target":"0","footnotes":""},"class_list":["post-16571","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/16571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/comments?post=16571"}],"version-history":[{"count":5,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/16571\/revisions"}],"predecessor-version":[{"id":25079,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/16571\/revisions\/25079"}],"up":[{"embeddable":true,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/736"}],"wp:attachment":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/media?parent=16571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}